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INTRODUCTION 
 
Future health care professionals must have not only profound theoretical knowledge, but 
also skills to apply it in their clinical practice. All the fundamental and specific medical sciences 
make a basis for doctor`s clinical thinking and altogether with the accurate practical knowledge 
form not a student, but a professional, able to solve clinical problems and self-educate. 
This guideline is built according to the algorithm, with is followed by a clinician at 
establishing the correct diagnosis and prescribing the proper treatment. It helps to precisely 
understand how to treat themanage the main disease, but also how to deal with the patient`s 
comorbidities and how to assess the patient`s risks for developing other diseases, and thus, prevent 
it.  
To turn learning into an interactive and creating process, each chapter is accompanied by 
augmented reality elements, which is not only helpful for acquiring practical skills, but also for 
involving the education receiver into the atmosphere of doctor-patient communication.  
The first part of the guideline is built in the way that turns a diagnosis into a step-by-step 
algorithm, in which every step is profoundly reasoned and clinically based. All the diagnosis criteria 
are contemporary and based on clinical trials and up-to-date international guidelines. 
Establishing a clinical diagnosis is based on determining the signs, symptoms, and 
syndromes of a particular disease. 
A sign is an indication of any objective evidence of a disease which is perceived by the 
physician, as opposed to the subjective sensations (symptoms) of the patient. 
A syndrome is a group of signs with a common pathogenesis. 
A disease is a combination of signs and/or syndromes with a common aetiology. 
The milestone in clinical examination is making a diagnosis. The physician analyses all 
obtained information from interviewing the patient as well as objective examinations to establish a 
preliminary diagnosis. The next step involves using additional objective methods in substantiating 
the preliminary diagnosis. 
Laboratory and instrumental investigations (additional diagnostic methods) must be 
supporting evidence in establishing the basic diagnosis and the diagnoses of complications. The 
choice of the volume of additional diagnostic methods requested by the physician should depend on 
the results of all obtained information. The requested investigations should be focused on 
confirming the preliminary diagnosis, basic diagnosis, and diagnoses of complication separately. 
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Individual examination of patients gives a real opportunity to arrange theoretical knowledge 
in order to form a proper clinical judgment. 
Finally, it is important to note that clinical endocrinology characterizes a multidisciplinary 
approach in combining knowledge from different medical fields.  
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ABBREVIATIONS 
 
ADA  American Diabetes Association 
BMI Body mass index 
CKD Chronic kidney disease 
CVD Cardiovascular disease 
DF Diabetic Foot 
DKA Diabetic ketoacidosis 
DN Diabetic Neuropathy 
DM Diabetes mellitus 
DR Diabetic Retinopathy 
IGT Impaired glucose tolerance 
DPP-4 Dipeptidyl Peptidase-4 
IAA 
ICA 
Autoantibodies to insulin 
Autoantibodies to islet cell 
IFG Impaired fasting glucose 
FPG Fasting plasma glucose 
GLP-1 Glucagon-Like Peptide-1 
GFR 
GTT 
Glomerular filtration rate 
Glucose Tolerance Test 
HbA1c Glycated haemoglobin 
LADA 
MODY 
Latent autoimmune diabetes in adults 
Maturity Onset Diabetes Mellitus in Young 
OGLD Oral Glucose-Lowering Drugs 
OGTT Oral Glucose Tolerance Test 
PAD Peripheral Artery Disease 
PPG Postprandial plasma glucose 
SGLT-2 Sodium-Glucose Cotransporter- 2 
T1DM Type 1 Diabetes Mellitus 
T2DM Type 2 Diabetes Mellitus 
WHO World Health Organization 
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1. DIAGNOSIS OF DIABETES MELLITUS AS THE BASIC DIAGNOSIS 
1.1. Definition and Classification of Diabetes Mellitus 
 
Diabetes mellitus (DM) is a heterogeneous group of metabolic diseases characterized by 
chronic hyperglycaemia due to absolute/relative insulin insufficiency or peripheral insulin 
resistance. 
DM can be classified as follows: 
I. According to types by the World Health Organization (WHO), 1999: 
1. DM type 1 (results from β-cell destruction, leading to absolute insulin deficiency), 
including LADA-diabetes. 
2. DM type 2 (results from a progressive insulin secretory defect on the background of 
insulin resistance). 
3. Other specific types of diabetes (secondary diabetes): 
a. monogenetic defects in ß-cells function (MODY – maturity onset diabetes of the 
young); 
b. genetic defects in insulin action (leprechaunism, Rabson-Mendenhall syndrome); 
c. diseases of the exocrine pancreas (pancreatitis, cystic fibrosis, trauma, 
pancreactomy, etc.); 
d. endocrinopathies (e.g., thyrotoxicosis, acromegaly, Cushing’s syndrome, 
glucagonoma, pheochromocytoma); 
e. associated with other genetic syndromes: Klinefelter’s syndrome, Down’s 
syndrome, Turner’s syndrome, etc.; 
f. drug- or chemical-induced DM due to their toxic effects on ß-cells. 
4. Gestational diabetes (found in pregnant women especially in the second and third 
trimesters of pregnancy). 
II. According to degree of DM severity (based on the methods used to achieve DM 
compensation and the degree of chronic complications). 
1. Mild degree. 
2. Moderate degree. 
3. Severe degree. 
III. According to the degree of compensation (based on the patient’s clinical state and laboratory 
parameters). 
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1. Compensation state. 
2. Subcompensation state. 
3. Decompensation state. 
IV. According to the complications of DM (hypoglycaemic and hyperglycaemic comas). 
A. Acute complications. 
1. Hypoglycaemic coma. 
2. Diabetic ketoacidotic coma (DKA). 
3. Hyperosmolar coma. 
4. Lactacidemic coma. 
B. Chronic complications (macroangiopathy and microangiopathy): 
1. Microangiopathy complications. 
1) diabetic retinopathy; 
2) diabetic nephropathy; 
3) diabetic neuropathy. 
2. Macroangiopathy complications. 
1) cardiovascular diseases;  
2) cerebrovascular diseases; 
3) diabetic angiopathy of the lower extremities. 
NB: Detailed explanations of the various classifications are found in the respective sections 
below. 
1.2. Algorithm in Making a Proper Diagnosis of Diabetes Mellitus 
 
A proper understanding of DM and diagnosing is best done with the help of understanding 
the aetiology and pathogenesis of DM and hence following the algorithms in diagnosing diabetes 
mellitus as elaborated below. 
DIAGNOSIS OF DIABETES MELLITUS 
The preliminary diagnosis of DM is established based on the physician’s primary evaluation 
of the patient’s state, including patient’s complaints, anamnesis and general objective clinical 
examination of the patient. 
CLINICAL DIAGNOSIS OF DM 
In order to establish a clinical diagnosis, the physician must substantiate the preliminary 
diagnosis with the help of objective additional investigative methods (laboratory and instrumental 
data). 
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1.3. Basic Diagnosis 
 
The basic diagnosis of DM consists of 3 parts: 
1. Type of DM. 
2. Degree of DM severity. 
3. State of DM compensation/decompensation. 
 
The basic diagnosis of DM should be done based on the information gathered by the 
physician from the patient to support the presence of the main triad of symptoms of DM and by the 
lab verification. Clinical triad includes: 
1. Polyuria (increased urination). 
This could either be nocturnal polyuria. Normal frequency of daily urination is 3 times (2 times 
in the day and 1 time at night). 
2. Polydipsia (increased thirst thus requiring more fluid intake).  
3. Loss of weight (for type 1 DM from normal body weight till cachexia, while for type 2 DM from 
one degree of obesity to the other). 
NB: The main aim of establishing the basic diagnosis is: 
1. To confirm the preliminary diagnosis through information gathering (complaints and 
anamneses). 
2. To set a base framework to perform additional diagnostic methods to confirm the basic 
diagnosis. 
3. To establish a base for determining the type of DM, severity of DM and diagnoses of the 
chronic complications of DM. 
Verification of Diagnosis of DM 
Verification of the basic diagnosis of DM involves performing laboratory diagnostic 
methods: 
1. Fasting plasma glucose level determination (FPG).  
2. Postprandial plasma glucose (PPG) level determination. 
3. HbA1c. 
Types of tests for determining blood glucose level in DM 
1. Fasting glucose – blood glucose level in the morning before breakfast, after preliminary 
fasting > 8 h. It can sometimes be referred to as “preprandial”, which means “before meal”. 
2. Postprandial test is performed at any time of the day. 
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Additional tests, recommended by ADA, 2020.  
1. Peak prandial glucose – blood glucose level 1 h after meal. Sometimes it can be measured at 
1-2 h after meal interval. 
2. Oral glucose tolerance test (OGTT) is performed in the fasting state, after preliminary fasting 
> 8 h by administering an oral glucose load. It is done by measuring blood glucose level 
twice (before and 2 h after taking oral glucose load). 
3. HbA1c – a test which reflects mean blood glucose level for the last 3 months before taking a 
blood sample. It measures the amount of haemoglobin attached to glucose (glycated 
haemoglobin). 
 
The OGTT rules: 
1. For adults 75 g of glucose are dissolved in 200 to 300 ml of water.  
2. For kids: 1.75 g of glucose per kg (1.75 g/kg) of body weight, but not more than 75 g should 
be dissolved in 200 to 300 ml of water and drunk for 3 to 5 min). 
However, in order to establish the basic diagnosis of DM, it is recommended to use two 
separate test samples. 
NB: The OGTT is not recommended for routine clinical use, it is indicated for diagnosing: 
1. Impaired glucose states, i.e., impaired fasting glucose state (IFG) and impaired glucose 
tolerance (IGT), which are asymptomatic disorders of carbohydrate metabolism. 
2. DM, when the available data for the verification of DM is not enough to establish the basic 
diagnosis of DM. 
  
Figure 1 – Types of glucometers
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Table 1 – Diagnostic criteria for diabetes and other disorders of carbohydrate 
metabolism (WHO, 2006) 
 
Diagnosis 
Determination of 
glucose in blood 
Capillary blood 
glucose parameter 
Plasma venous blood 
glucose level 
Normal Fasting 
3.3 to 5.5 mmol/l  
(< 100 mg/dl) 
– 
 After 2 h, after GTT 
< 7.8 mmol/l 
(< 140 mg/dl) 
– 
Diabetes Fasting 
> 6.1 mmol/l 
(< 110 mg/dl) 
> 7.0 (> 126 mg/dl) 
 After 2 h, after GTT 
> 11.1 mmol/l 
(< 200 mg/dl) 
> 11.1 (> 200 mg/dl) 
Impaired glucose 
tolerance 
Fasting 
5.6–6.1 mmol/l 
(100 to 110 mg/dl) 
< 7.0 (< 126 mg/dl) 
 After 2 hours after GTT 
7.8 to 11.0 mmol/l 
(140 to 200 mg/dl) 
> 7.8 (> 140 mg/dl) 
and < 11.1 
(< 200 mg/dl) 
Impaired fasting 
glucose 
Fasting 
5.6 to 6.1 mmol/l  
(100–110 mg/dl) 
> 6.1 (> 110 mg/dl) 
and < 7.0 
(< 126 mg/dl) 
 
After 2 hours 
 (if defined) 
< 7.8 mmol/l  
(< 140 mg/dl) 
< 7.8 (< 140 mg/dl) 
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Figure 2 – How to use a glucometer 
 
Rules of glucometer use: 
1. Glucometers work with the help of a plastic strip covered with glucose oxidase. 
2. The strips are used only once and discarded. 
3. 0.2 to 1.1 µl of blood is sampled from the finger for testing using a lancing device, which is 
bought alongside the glucometer. 
4. It takes about 30 seconds to get the desired result. 
5. To convert mmol/l to mg/dl, multiply by 18. 
NB: Note should be taken when reading glucometers based on their calibration because 
there exist capillary blood calibrated glucometers and plasma venous blood calibration. 
Glucose plasma levels are usually from 10 to 15% higher than capillary blood and even 
more after meals. 
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1.3.1. Determining the Type of Diabetes Mellitus 
 
Determining the type of DM by WHO (1999) classification (see p. 8): 
1. Anamnesis gathering to determine the conditions of DM onset (age, weight loss, DKA) and 
previous laboratory data. 
2. Laboratory data: 
a) serum C-peptide and insulin; 
b) determination of autoantibodies to glutamic acid decarboxylase, insulin and islet cell 
autoantibodies. 
The main task at this stage is differentiating between type 1 (about 5-10% of all diabetes 
cases) and T2DM (> 85 % of all diabetes cases).  
 
Other specific types of DM 
Late autoimmune diabetes of adults (LADA) 
 
LADA is a subtype of type 1 DM, which is characterized by the following features: 
- onset at > 30 years; 
- presence of characteristic autoantibodies; 
- patients do not require intensive basic-bolus insulin therapy; 
- faster decline in C-peptide compared to type 2 DM; 
- lower BMI than typical for type 2 DM. 
The main differences from type 1 DM are slower progression and later onset. And the 
differences from type 2 diabetes are the absence of insulin resistance, autoimmunity and faster 
occurrence of insulin therapy necessity. 
The diagnosis is confirmed via typical antibodies detection. Treatment should be aimed at 
preserving residual beta-cells` function, as well as at adequate glycaemic control. Patients need 
to be administered insulin therapy when the function of beta cells is lost. The period from 
LADA onset to absolute insulin deficiency is variable and can be prolonged by treatment, aimed 
at preserving beta-cells’ function, decreasing insulitis and reducing hyperglycaemic stress. The 
options include insulin, DPP-4 inhibitors and GLP-1 agonists. 
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Maturity onset diabetes of the young (MODY) 
 
Each MODY type is caused by single mutation in a gene, which is responsible for beta-cells 
function, development or regulation. This leads to impairment in glycemia regulation because of 
glucose-sensing or insulin release disturbances.  
 Signs to suspect MODY: 
 - strong family history of diabetes; 
- onset at young age, especially at first 6 months of life; 
- lack of insulin resistance evidence; 
- absence of type 1 diabetes features (i.e., absence of GABA antibodies or normal C-peptide 
levels). 
Diagnosis is confirmed via genetic testing. MODY 1 and 3 require sulfonylurea treatment. 
MODY 2 can usually be managed by regular exercises and diet. 
 
Table 2 – Most common MODY types 
MODY 
type 
Defected 
gene/protein 
Prevalence 
Description 
MODY 1 Hepatocyte 
nuclear factor 
4α 
5–10 % HNF4α responds for the early development of the 
pancreas, liver and intestines. Responds to sulfonylurea 
treatment. 
MODY 2 Glucokinase 30–70 % Mild change in glucose tolerance test results. Can be easily 
managed through the diet and physical activity 
MODY 3 Hepatocyte 
nuclear factor 
1α 
30–70 % HNF1α is responsible for beta cells` differentiation. 
Disturbances in its function lead to reduction of beta cells` 
number and impairment of their function. Responds to 
sulfonylurea treatment. 
MODY 4 PDX-1 
homebox on 
chromosome 
12 
< 1 % Pdx-1 is responsible for prenatal pancreas development. It 
also plays an important role in insulin and somatostatin 
regulation. 
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Table 3 – Differences between type 1 and type 2 DM 
 
Metabolic syndrome 
 Metabolic syndrome is a combination of metabolic disturbances, that provoke and accelerate 
each other. It is composed of the following criteria. 
1. Abdominal obesity (>102 cm in men, >88 cm in women). 
2. TAG > 1.7 mmol/l. 
3. HDL < 1.03 in men, <1.3 in women. 
4. The level of fasting glucose > 5.5 mmol/l. 
5. SBP > 130 mmHg, or DBP > 85 mmHg. 
Parameter Type 1 DM Type 2 DM 
Onset age In childhood mostly Mostly in adults 
Percentage of total DM 
cases 
About 5–10 % of all DM 
cases 
> 85 % of all DM cases 
Aetiology Autoimmune attack on 
insulin and β-cells of the 
pancreas leading to an 
absolute decrease or 
absence of insulin 
Increased resistance to insulin of target 
organs` receptors. Hence, insulin might be 
produced in normal quantities or in large 
amounts, but their effect is low 
Association with obesity Absent Present (even though relative weight loss 
after overweight has been noted) 
Ketoacidosis and 
ketonuria 
Present Absent 
Treatment Mainly by insulin 
replacement therapy 
Using anti-diabetic drugs but occasionally 
insulin replacement therapy is used in case of 
severe state or high resistance to oral 
hypoglycaemic drugs 
C-peptide and insulin in 
blood test 
Low High or normal (low in later stages) 
Autoimmune antibodies 
to insulin 
Present Absent 
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If 3 or more of the mentioned are present, the patient is at a high risk of cardiovascular or 
cerebrovascular accident.  
Body mass index (BMI) is an indicator, that shows relation between the patient`s weight 
and height. It is used for determining the grade of obesity. 
BMI = weight, kg / (height, m)2 
The normal range is 18.5-24 kg/m2 
Homeostatic model assessment of insulin resistance (HOMA-IR) – is a method for 
evaluating beta-cells` function and insulin sensitivity. 
HOMA-IR = (fasting insulin, mcU/ml * fasting glucose, mmol/l) / 22.5 
The normal range is < 3. 
 
Figure 3 – Insulin resistance progression it type 2 DM 
1.3.2. Determining Degree of DM Severity 
 
The degree of severity of DM is determined by the following parameters: 
1. Presence or absence of chronic complications and which stage of severity of these chronic 
complications (retinopathy, nephropathy, neuropathy, macroangiopathy) determines the degree 
of severity of DM determined by laboratory and instrumental methods of investigation. 
2. Treatment scheme adopted to manage DM (diet, exercise, oral hypoglycaemic drugs and/or 
insulin therapy). 
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I. Mild severity:  
Absence or presence of early stages of chronic complications of DM.  
Treatment scheme: diet, physical exercises and lifestyle modification to normalize the condition. 
NB: Mild severity of DM is seen only in Type 2 DM since insulin nor are oral hypoglycaemic 
drugs required for management purposes. 
II. Moderate severity:  
Chronic complications from 1st–3rd stages. 
Treatment scheme: compensation reached only after insulin therapy for T1DM or after oral anti-
diabetic medications for T2DM. 
III. Severe state:  
Any chronic complications of the 3rd and 4th stages. Insulin is for treatment: 
1. Increased dose of administered insulin in T1DM. 
2. Start administration of insulin replacement therapy in T2DM due to resistance to sulfonylureas. 
 
Figure 4 – Glucose monitoring alarm points 
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1.3.3. Determining the State of DM Compensation/Decompensation  
 
There are three states of compensation in DM: 
1. Compensation. 
2. Subcompensation. 
3. Decompensation. 
The state of compensation is determined by two major parameters: 
1. Presence or absence of main triad of DM. If present, then state is said to be decompensation. 
If absent, then compensation. 
2. According to laboratory data obtained from fasting and postprandial glycaemic levels, and 
level of glycated haemoglobin in blood (HbA1c). See summary in the table below. 
 
Table 4 – Criteria of compensation of carbohydrate metabolism in type 1 and type 2 
diabetes mellitus  
Indicator Compensation Subcompensation Decompensation 
HBA1c* < 7.0 7.1 – 7.5 > 7.5 
 
Capillary 
blood 
glucose, 
mmol/l 
Fasting glucose test  5.0 – 6.0 6.0 – 6.5 > 6.5 
Postprandial 
glycaemia 
(2 h after meals 
7.5 – 8.0 
 
8.1 – 9.0 
 
> 9.0 
Glycaemia bedtime 6.0 – 7.0 7.1–7.5 7.5 
* Normal HBA1c from 4 to 6% 
 
Figure 5 – One strip test for HbA1c evaluation 
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2. DIAGNOSIS OF CHRONIC COMPLICATIONS OF DIABETES 
MELLITUS 
 
Classification of chronic complications of diabetes mellitus: 
1. Microangiopathic complications: 
1) diabetic neuropathy; 
2) diabetic retinopathy; 
3) diabetic nephropathy. 
2. Macroangiopathic complications: 
1) macroangiopathy of lower extremities; 
2) cerebrovascular angiopathy; 
3) cardiovascular diseases: 
– ischaemic coronary heart diseases (myocardial infarction). 
 
2.1. Microangiopathy 
2.1.1. Diabetic Neuropathy 
It should be understood, that diabetic neuropathy is the earliest (first) chronic complication 
of DM and it is seen in all patients but in varying degrees of clinical manifestations, hence the need 
for a better classification occurs in order to properly observe the clinical changes. 
Pathogenesis 
DN is mostly caused by microangiopathy of vasa nervorum. Another contributing 
mechanism of nerve damage is the direct nerve damage by disturbances of glycaemia levels. The 
process of nerve lesion can be described with the help of the term “primary axonopathy”. It refers to 
primary damage of the nerve axon, which is followed by demyelination. It then results into axonal 
current insufficiency and reduction of intracellular energy production. In the case of DN, most of 
the damage done can be successfully reversed by the proper therapy and adequate glycaemic 
control. 
20 
 
Classification of diabetic neuropathy 
There exist different approaches to classification of diabetic neuropathy (DN): based on 
clinical manifestations, pathogenesis, location, onset and other features. Clinical classifications 
include up to 20 types of DN.  
1) Symmetrical polyneuropathies: 
a. sensorimotor  
b. sensory 
2) Autonomic neuropathy 
a. cardiovascular autonomic neuropathy 
i. tachycardia at rest 
ii. postural hypotension 
iii. silent myocardial infarction/ischaemia 
b. gastrointestinal autonomic neuropathy 
i. gastroparesis 
ii. diabetic diarrhoea 
iii. constipation 
c. genitourinary autonomic neuropathy 
i. urinary retention 
ii. impotence 
d. decreased hypoglycaemia perception 
3) Focal and multifocal neuropathies  
a. radiculoplexus neuropathies 
i. lumbosacral 
ii. thoracic 
iii. cervical 
b. mononeuropathies 
i. Median neuropathy at the wrist  
ii. Ulnar neuropathy at the elbow  
iii. Peroneal neuropathy at the fibular head 
c. cranial 
i. Oculomotor palsy  
ii. Abducens palsy 
d. proximal motor (amyotrophy)  
 
Clinical presentation 
Typical DN is described as a symmetrical, length-dependent sensorimotor polyneuropathy 
attributable to metabolic and microvessel alterations as a result of chronic hyperglycaemia exposure 
and cardiovascular risk covariates.  
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Sensorimotor DN 
Sensorimotor DN usually has an insidious onset with paraesthesia or numbness. It is more 
likely to be found on screening, than to be a main complaint. It starts from the soles and toes, and 
then spreads upside symmetrically.  In severe cases it may also affect fingers and hands. It affects 
all sensory modalities and results in reduced vibration perception threshold, pinprick, fine touch and 
temperature sensation. Loss or reduction of vibration sensation and/or absent ankle reflexes are the 
first signs found. An inability to fill 10g monofilament is a risk factor for ulceration. Less often, 
allodynia is a presenting sign – skin is tender and sensitive to touch.  
Mononeuropathies 
Diabetic mononeuropathies may be spontaneous or occur because of nerve entrapment or 
external pressure. Most commonly carpal tunnel syndrome is found. Symptoms include pain, 
numbness, paraesthesia beginning in fingers. The pain can irradiate to elbow and shoulder. Motor 
component of neuropathy presents as troubles taking small objects and clenching a fist. The disease 
progresses to partial or total loss of control over the hand. 
Cranial mononeuropathies tend to occur suddenly and have a good prognosis. Most 
commonly seen (but still infrequent) are the palsies of III and VI nerves. Spontaneous recovery is 
slow over several months.  
Autonomic neuropathy 
Cardiovascular autonomic DN 
1) Tachycardia at rest can be the first sign of autonomic cardiovascular DN. It is 
characterized as resting heart rate of up to 140 bpm, which becomes fixed as the disease 
progresses. This means, that, following the heart denervation, heart rate loses ability to 
increase or decrease in response to stimuli. 
2) Postural hypotension is caused by absence of compensatory vasoconstriction in response 
to moving the body to upward position. When any person stands up, a significant part of 
circulating blood volume moves downwards, affected by gravity. Peripheral 
vasoconstriction is a normal compensatory response to that, and if it doesn`t occur, 
patient experiences hypotension up to collapse.  
3) Silent myocardial ischaemia occurs in more than 60% of all patients with diabetes. 
Autonomic neuropathy can mask ischaemic pain, thus removing the limiting factor for 
physical or stress activity. Patients don`t feel the need to rest and take nitrates which can 
lead to myocardial infarction. Myocardial infarction is the main cause of deaths in 
patient with diabetes. It is accompanied by atypical pain or is painless (silent) in more 
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than 30% of all cases associated with diabetes. Atypical pain syndrome leads to late 
diagnostic and delays the necessary treatment. 
Gastrointestinal autonomic DN 
1) Gastric motility disorders, as well as oesophagus motility disorders, result from vagus 
nerve impairment. Symptoms include nausea, dysphagia, postprandial fullness, recurrent 
vomiting and electrolyte disbalance in severe cases. 
2) Diabetic diarrhoea can be explained both by disturbances of intestine innervation and 
overgrowth of gastrointestinal flora. Characteristic features include imperative urges to 
defecate and nocturnal diarrhoea. Patients suffer from 15-20 stools daily, which can lead 
to hypoglycaemia. 
3) Constipation. Gastrointestinal DN can result into hyper- or hypomobility of the affected 
gastrointestinal segment. Diminished colon peristalsis can lead to decrease in stool 
regularity up to 1-2 times a week.  
Genitourinary autonomic DN 
1) Urinary retention is clinically noticeable in advanced stages. Initial symptoms include 
the enlargement of the bladder and increased postvoiding residual volume. Urinary 
retention may promote urinary infections perceptivity. 
2) Impotence occurs in response to disorganization between parasympathetic innervation, 
which promotes erection, and sympathetic innervation, which promotes ejaculation.  
Decreased hypoglycaemia perception can be associated with autonomic neuropathy. It is 
characterized as a state, when the patients doesn`t experience typical symptoms of hypoglycaemia. 
The other causes for this state include hypoglycaemia during sleep or physical exercises and 
administration of non-selective beta-blockers. 
Rare DN 
Insulin neuritis (Ellenberg syndrome) 
It occurs in patients who overwent rapid glycaemia reduction with high doses of insulin after 
a long period of inadequate glycaemic control. The main symptom is acute onset of intensive pain 
6-8 weeks after rapid decrease of glycaemia. It is accompanied by rapid weight loss (diabetic 
cachexia) which can be misinterpreted as a result of proper glycaemic control. Pain is often 
described as 10/10 by patients. Pain-provoking factors are touching, non-painful irritants, bedsheets, 
clothes. Components of autonomic neuropathy may also be present. 
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Diabetic amyotrophy 
Symmetrical proximal motor neuropathy is one of the rare variants of DN. It has a subacute 
onset (several weeks or months). Symptoms include progressive weakness and atrophy of proximal 
leg muscles, sometimes – brachial muscles. Another presenting symptom is severe deep burning 
pain, which can keep patients awake at night and cause cachexia. Sensitivity disturbances are 
minimal or absent. This state may be misdiagnosed as a primary muscle damage or myelopathy.  
 
Instrumental diagnosis of diabetic neuropathy 
The diagnosis of diabetic motor neuropathy can be established by visual observation (signs 
of hyperkeratosis, skin dryness, ulcer formations, bone deformations of hands and/or feet), objective 
evaluation as well as instrumental diagnostic methods, e.g., ultrasound, electromyography; for 
osteoarthropathy X-ray, CT-densimetry, etc. 
 
 
Figure 6 – Lateral (left) and anteroposterior (right) radiograph views of feet deformations 
caused by diabetic osteoarthropathy  
 
Evaluation of sensory diabetic neuropathy includes the use of diagnostic instruments which 
are indicated below. 
I. General recommendations. 
1. Explain each test before you do it.  
2. Unless otherwise specified, the patient’s eyes should be closed during the actual testing.  
3. Compare symmetrical areas on the two sides of the body.  
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4. Also compare distal and proximal areas of the extremities.  
5. When you detect an area of sensory loss map out its boundaries in detail. 
II. Vibration perception. 
1. 1. Use a low-pitched tuning fork (128 Hz). It usually has a 0-8 scale and the result of test is 
percepted by the examiner via optical illusion, which appears on a scale due to vibration. A 
normal vibration sense is > 6 points, while < refers to high ulceration risk. 
a) Perform a test with a non-vibrating tuning fork first to ensure that the patient is responding 
to the correct stimulus. You may also demonstrate which feeling should a patient respond to 
on a probably unaffected region. 
b) Place the stem of the fork over the distal interphalangeal joint of the patient’s index fingers 
and big toes.  
c) Ask the patient to tell you when he stops feeling vibration and note the result. 
2. 2. If vibration sense is impaired proceed proximally. Suggested regions to perform the test: 
wrists, elbows, medial malleoli, patellas. 
 
Figure 7 – Neurological low-pitched tuning fork 
 
3. Electronical devices can also be used to measure vibration perception threshold: 
neurothesiometer and biothesiometer. They send vibration of different intensities applied to 
the big toe. The threshold is measured in volts per micrometre (VPT), and the normal 
sensation refers to < 25 V. 
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Figure 8 – Electronical devices for vibration perception measurement 
 
III. Subjective light touch. 
1. Use your fingers to touch the skin lightly on both sides simultaneously.  
2. Test several areas on both the upper and lower extremities.  
3. Ask the patient to tell you if there is difference from side to side or other “strange” sensations. 
IV. Position sense. 
1. Grasp the patient’s big toe and hold it away from the other toes to avoid friction. Move the 
finger up and down with the patient’s eyes closed and ask the patient to identify the direction 
you move the toe. 
2. If position sense is impaired move proximally to test the ankle joint. 
3. Test the fingers in a similar fashion. 
4. If indicated, move proximally to the metacarpophalangeal joints, wrists, and elbows. 
V. Dermatomal testing. 
It is performed to evaluate focal or multifocal neuropathy. With the use of all mentioned methods 
(most commonly, pinprick and light touch sensation) symmetrical dermatomes are tested and 
compared. 
VI. Tactile and pain sensation.  
Use Semmes-Weinstein monofilament for touch sensation threshold evaluation and a sharp sterile 
object (pin) to test pain sensation. The monofilament is applied perpendicular to the skin until it 
bends or buckles from the pressure, left in place for approximately one second and then moved 
away. 
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Figure 9 – Testing tactile sensation with Semmes-Weinstein  
monofilament 
 
 
Semmes-Weinstein monofilament instructions 
 Semmes-Weinstein monofilament helps to evaluate A-beta fibers, measuring the patient`s 
sensation to light touch. 
1. Explain the procedure to the patient and instruct him/her how to respond to the stimuli. 
2. Take note of areas with corns, calluses, burns or other types of defects. 
3. Support the patient’s extremity on a flat, stable surface. The test should be done in a 
comfortable atmosphere with the patient`s eyes closed. 
4. Press the monofilament on the skin at an angle of 900 until it bends. Hold it in this position for 
2 seconds and remove it. The stimulus is applied once, and the reaction indicates positively. 
Register the results using a circle to indicate sensitive zones and a cross to indicate lack of 
sensation 
NB: Before and after usage, the filament should be gently cleaned with a disinfectant. Do not 
use if it is bent or twisted. 
VII. Temperature sensation.  
Often omitted if pain sensation is normal.  
Use Tip Therm instrument with different properties of plastic and metal to generate 
sensations of different temperatures on the skin's surface. 
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 Apply both tips of the stick in turn at the dorsum of the feet and legs and ask the patient 
(with the eyes closed) to identify whether the stick is cold or hot. 
 
 
VIII. Pulsation. 
 
This is to rule out vascular damage. Normal pulse with other symptoms indicates more of 
neuropathic effect, whereas decreased or absent pulse points to vascular damage.  
Assess the pulse symmetry and artery amplitude of each leg.  
The Dorsalis Pedis Artery pulse is palpable on the dorsum of the foot in the first 
intermetatarsal laterally to the extensor tendon of the great toe.  
The Posterior Tibial Artery pulse can be examined behind and below the medial malleolus. 
 
 
Figure 11 – Palpation of the pulse on the Dorsalis Pedis Artery and Posterior Tibial Artery  
 
Figure 10 – Temperature sensory testing with Tip Therm  
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Figure 12 – Objective neurological examination 
 
Evaluation of diabetic neuropathy severity 
 Diabetic polyneuropathy is commonly staged as follows (Neuropathy Symptom Score) 
1. NO – no neuropathy 
2. N1 – positive objective signs without symptoms 
3. N2a – symptomatic mild diabetic polyneuropathy: sensory, motor or autonomic 
symptoms. Patient can heel-walk. 
4. N2b – severe symptomatic diabetic polyneuropathy. Patient is unable to heel-walk. 
5. N3 – disabling diabetic polyneuropathy. 
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Table 5 – Neuropathy Disability Score (NDS) 
 Right side Left side Summary 
Reflexes (0 – normal, 1 – decreased, 2 – absent) 
Knee reflex    
Ahillian reflex    
Sensitivity (0 – normal, 1 – impaired within toes, 2 – impaired from toes to the middle of the 
foot, 3 – impairment reaches ankles, 4 – impairment reaches knees) 
Pain    
Tactile    
Temperature    
Vibration sensitivity threshold 
1st finger    
Ankle    
Result: 0–4 points – normal, 5–13 – mild neuropathy, 14–28 – severe neuropathy 
 
Table 6 – Total Neuropathy Score (TNS) 
Parameter Score 
0 1 2 3 4 
Sensory 
symptoms 
Absent Limited 
to fingers 
and toes 
Symptoms 
extend to 
ankle or 
wrist 
Symptoms extend 
to knees or elbows 
Symptoms extend 
above knees or elbows 
/ symptoms lead to 
disabling 
Motor 
symptoms 
Absent Slight 
symptoms 
Moderate 
symptoms 
Patient requires 
help or assistance 
moving 
Paralysis 
Pain 
sensibility 
Within 
normal 
range 
Low in 
fingers or 
toes 
Low up to 
wrists or 
ankles 
Low up to elbows 
or knees 
Low in regions above 
elbows and knees 
Strength Normal Mild 
weakness 
Moderate 
weakness 
Severe weakness Paralysis 
Tendon 
reflexes 
Normal Ankle 
reflex 
reduced 
Ankle 
reflex 
absent 
Ankle reflex 
absent, others 
reduced 
All reflexes absent 
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Severity grade for TNS:  asymptomatic  0–1 – none (grade 0) 
       2–8 – minor (grade 1) 
     symptomatic  9–16 – moderate (grade 2) 
         17–24 – moderately severe (grade 3) 
       25–28 – severe (grade 4) 
Example of diabetic neuropathy diagnosis 
1. Acute bilateral lower extremity diabetic neuropathy sensory form. 
2. Chronic bilateral lower extremity diabetic neuropathy sensory form. 
NB: Regarding the other forms of neuropathy, they are important too for clinical 
knowledge but are not very important in establishing the diagnosis of diabetic neuropathy. To 
establish the diagnosis of diabetic neuropathy, pay more attention to the peripheral distal 
neuropathy and autonomic neuropathy as explained above. 
 
 
Treatment of diabetic neuropathy 
1. Vitamin therapy (Vit B-group complex).  
Thiamine (Vitamin B1) is a co-enzyme in several metabolic pathways of carbohydrates and 
branched-chain amino acids. Neurons receive chemical respiratory activity from the oxidation 
of carbohydrates, which is used to produce energy and maintain the correct structure of neurons. 
Pyridoxine (Vitamin B6) is a co-enzyme in several metabolic pathways of amino acid, 
carbohydrate and sphingoid bases. In addition, it is involved in the formation of haemoglobin.  
Cobalamin`s (Vitamin B12) main functions are the cellular replication and growth, as he is a 
cofactor in DNA synthesis, and in both fatty acid and amino acid metabolism. It regulates the 
maturation of red blood cells in the bone marrow and the normal functioning of the nervous 
system 
B-vitamins take part in the process of anaesthesia through effects on impaired axons impulse 
transmission, synthesis of inhibitory neurotransmitters and reduce oedematous neuronal 
processes. They can influence a broad range of neurological signs and symptoms like 
paraesthesia, diminished sensation of vibration and position, reluctant unsteadiness, depressed 
tendon reflexes, loss of memory, confusion, moodiness and loss of central vision (retinopathy). 
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Neurorubine combines three vitamins in high doses which are indispensable in the nervous 
system.  
 
Each ampoule contains: 
Vitamin Bl     (USP)                 200 mg 
Vitamin B6     (USP)                50 mg 
Vitamin B12     (USP)              1000 mcg 
Lidocaine HCl                          10 mg 
 
 
Each Lactab contains:  
Vitamin Bl     (USP)                 200 mg 
Vitamin B6     (USP)                50mg 
Vitamin B12     (USP)              1000 mcg 
 
 
Each Milgamma ampoule contains 2 ml:  
Cyancobalaminum  1 mg  
Pyridoxinum chloratim 100 mg 
Thiaminium chloratum 100 mg 
Lidocainium chloratum 20 mg 
 
  Each Milgamma Dragee contains: 
 Cyancobalaminum  250 mcg 
Benfotiaminum  50 mg 
 
 
 
2. Antioxidants. Alpha lipoic, Thioctic Acid  
Oxidative stress resulting from enhanced free-radical formation and/or defects in antioxidant 
defence is implicated in the pathogenesis of diabetic neuropathy. Markers of oxidative stress such 
as superoxide anion and peroxynitrite production are increased in diabetic patients in relation to the 
severity of polyneuropathy. Thioctic (α-lipoic) acid favourably influences the vascular 
abnormalities of diabetic polyneuropathy such as impaired microcirculation, increased indices of 
oxidative stress, and increased levels of markers for vascular dysfunction, such as thrombomodulin, 
albuminuria. Treatment using intravenous or per os form of thioctic acid 600 mg/day reduces the 
chief symptoms of diabetic polyneuropathy to a clinically meaningful degree, reduces neuropathic 
deficits and improves cardiac autonomic neuropathy.  
 
Figure 13 –  Neurorubine 
Figure 14  – Milgamma vials 
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3. Laser therapy in the treatment of neuropathic pain syndrome. 
The improvement of microcirculation and utilisation of oxygen in tissues as a result of low 
intensity laser therapy is intimately linked with positive influence on metabolism: higher level of 
oxidation of energy-carrying molecules of glucose, pyruvate, and other substances.  
Laser procedures have analgesics effect, show reliable rising tolerance of patients towards 
physical tolerance test, elongation of the period of painless remission. 
 
 
 
Figure 16 – Low intensity intravenous laser therapy 
 
Figure 15 – Alpha lipoic acid medications 
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4. Pain reduction. 
According to ADA, pregabalin, duloxetine and gabapentin are recommended as initial 
pharmacologic treatments for neuropathic pain in diabetes. Pregabalin is an antiepileptic drug. 
Treatment is initiated at 150 mg/day; maximal dose is 600 mg/day. Diabetic patients taking 
pregabalin may experience weight gain and it also causes a dose-dependent withdrawal syndrome. 
Gabapentin is initiated at 300 mg once a day and standard dose is 300 mg 3 times a day. Duloxetine 
is a serotonin and norepinephrine reuptake inhibitor. Initial dose is 60 mg/day.  
 
Figure 17 – Pain reduction medications: duloxetine 30 mg, pregabalin 75 mg 
 
2.1.2. Diabetic Nephropathy 
 
Diabetic nephropathy is one of the chronic complications of DM. It is diagnosed by clinical 
manifestations (signs and symptoms), objective examination of patient, laboratory diagnosis and 
instrumental diagnosis. 
Complaints and objective examination of diabetic nephropathy include: 
1. Hypertension (secondary to kidney damage). 
2. Generalized oedema starting from the face (during objective observation and palpation of the 
patient). 
3. Polyuria (usually nocturnal polyuria) at initial stages of the disease which gradually decreases to 
oliguria/anuria in the 4th and 5th stages of diabetic nephropathy leading to chronic kidney disease 
(CKD). 
4. Pollakiuria (increased frequency of daily urination > 3 times). 
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NB: Pain during lumbar percussion (positive Pasternatsky sign) is not specific for diabetic 
nephropathy. 
Laboratory diagnosis of chronic diabetic nephropathy: 
1. General urine analysis and 24 h urine control (to determine pollakiuria and polyuria). 
2. Nechiporenko test (to rule out infections probably causing pyelonephritis as well as other 
infections of the urinary system). 
3. Complete blood count and biochemical profile (to determine the blood levels of urea and 
creatinine in order to determine the staging of diabetic nephropathy). 
Biopsy: it helps establishing the early morphological structure changes in the kidney (see 
classification of nephropathy by Mogensen C. E.).   
Instrumental methods: 
1. Ultrasound investigation. 
2. Computer tomography. 
Classification of diabetic nephropathy 
1. According to the stages of development of diabetic nephropathy (according to C. E. Mogensen). 
Criteria for classification: 
a) glomerular filtration rate (GFR) by Roberg’s probe (Normal GFR = 80 to 120 ml/min); 
b) proteinuria (24 h protein analysis of urine). 
 
Figure 18 – Fast microalbuminuria assessment test 
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Table 7 – Classification of diabetic nephropathy by C. E. Mogensen 
 
Stage of diabetic nephropathy GFR Albuminuria Other findings 
Preclinical stages 
(compensation 
stages) 
Stage 1 
Hyperfunction 
of kidneys 
Increased  
>140 ml/min 
 
Normoalbuminu
ria (< 30 
mg/day) 
1. Increasing of renal 
blood flow. 
2. Hypertrophy of 
kidneys 
 
Stage 2 
Initial 
structural 
changes of 
kidneys tissue 
The high level 
of GFR is kept 
120–
140 ml/min 
Normoalbuminu
ria 
(< 30 mg/day) 
1. Thickening of the 
basal membranes of 
capillaries glomeruli. 
2. Dilation of 
mesangium 
 
Clinical stage 
(subcompensation) 
Stage 3 
Initial 
nephropathy 
(Start of kidney 
dysfunction 
with slight 
calibrations to 
normal 
function) 
GFR 
decreases to 
normal value 
90–
120 ml/min 
Microalbuminur
ia (from 30 to 
300 mg a day) 
 
1. Transient arterial 
hypertension. 
2. Transient oedema 
Stage of nephrotic 
syndrome* 
(decompensation) 
Stage 4 
High grade 
nephropathy 
GFR is 
decreased  
< 90 ml/min 
Proteinuria      
(> 300 mg/day) 
 
1. Nephrotic syndrome 
present. 
2. Arterial 
hypertension 
Stage of kidney 
failure 
(decompensation) 
Stage 5 
Uraemia 
Severe 
decreasing of 
GFR 
< 10 ml/min 
 
Proteinuria  
(> 300 mg/day) 
 
1. Arterial 
hypertension. 
2. Symptoms of 
intoxication 
* Nephrotic syndrome criteria: massive proteinuria > 3.5 g/day; hypercholesterolaemia, 
hypertension and generalized oedema, hypalbuminaemia < 25 g/l.  
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2. According to albuminuria. 
Criteria of classification: 
a) 24 h analysis of albumin in urine; 
b) clinical urinalysis. 
 
Table 8 – Classification of diabetic nephropathy by albuminuria 
Parameter Clinical urine analysis 
24 h urine 
analysis 
Albumin (urine) to 
creatinine (urine) ratio, 
mg/mmol 
Male Female  
Normal 
albuminuria 
< 20 mg/min < 30 mg 
< 2.5 < 3.5 
Microalbuminuria 
From 20 to 
200 mg/min 
From 30 to 
300 mg 
2.5–25 3.5–35 
Macroalbuminuria > 200 mg/min > 300 mg > 25 > 35 
 
N.B. GFR has different standards for diabetic nephropathy staging, than for chronic kidney 
disease. I.e., GFR of 90 ml/min refers to normal kidney function in patient without diabetes, and 
to stage 4 of diabetic nephropathy. 
 
Table 9 – Chronic kidney disease classification (according to Kidney Disease Quality 
Initiative 
Stage GFR, ml/min 
1 – Kidney damage with normal kidney function > 90 
2 – Kidney damage with mild loss of kidney function 89–60 
3a – Mild to moderate loss of kidney function 59–45 
3b – Moderate to severe loss of kidney function 44–30 
4 – Severe loss of kidney function 29–15 
5 – Kidney failure < 15 
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GFR calculations 
Glomerular filtration rate (GFR) is considered as the best way to assess global renal function. 
Nowadays GFR estimations (based on creatinine equations) are most often used but measuring 
“true” GFR is still important in clinical practice, especially in particular patients. 
1. Test of Reberg 
GFR =(Cu/Cp) *V 
Cu – urine creatinine; Cp – plasma creatinine; V – urine volume, ml/min 
N.B.: the Danish physiologist, Paul Brandt Reberg was the first to use and define the 
concept of clearance. Reberg studied the urea and creatinine clearances on himself to prove that 
kidney has a filtrating and not only a secreting action (Reberg, 1926). 
NB: It should be noted that a normal Reberg’s probe (from 80 to 120 ml/min) in healthy 
individuals is equivalent to 3rd stage of nephropathy in diabetic patients. 
2. Creatinine-based equations: 
Estimated GFR (GFRe) using Cockroft-Gault formula:  
GFRe (ml/min) = 1.228 X (140 – Age) X Body Weight (kg) X 0.85 (for women) or 1.00 (for Men) 
                                            Plasma creatinine level (µmol/L) 
       
Estimated GFR (eGFR) using Modification of Diet in Renal Disease (MDRD) formula 
eGFR = 186 x (Plasma creatinine, mg/dl) – 1,154 x (Age, years)–0.203  
 
3. CKD-EPI formula is the most useful, as it helps to avoid analytical mistakes.  
GFR = 141 * min (Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if 
black]; 
where  
к – 0.7 for female, 0.9 for male; 
α – (-0.329) for females, (-0.411) for males 
GFR can otherwise be calculated with the use of broadly available online calculators. 
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Treatment of diabetic nephropathy 
To treat hypertension caused by diabetic nephropathy, angiotensin converting enzyme 
(ACE) inhibitors and/or angiotensin receptor blockers (ARB) are used. 
B-blockers and calcium channel blockers are not recommended in treating hypertension 
caused by diabetic nephropathy. 
NB: For detailed medications and doses for treating arterial hypertension of different 
aetiologies, see appendix В below. 
 
Table 10 – Angiotensin converting enzyme (ACE) inhibitors 
 
ACE inhibitors 
Captopril 12.5–50 mg once daily 
Enalapril 5–40 mg once daily or in two equally divided 
doses 
Fosinopril 10–40 mg once daily 
Lisinopril 5–40 mg once daily 
Peridopril erbumine 4–8 mg once daily 
Peridopril arginine 5–10 mg once daily 
Quinapril 5–40 mg once daily or in two equally divided 
doses 
Ramipril 2.5–10 mg once daily or in two equally divided 
doses 
Trandolapril 2–4 mg once daily 
 
Table 11 – Angiotensin receptor blockers (ARB) 
 
 
Sodium-glucose cotransporter 2 inhibitors might also be used but consider side effects 
and cost. Dietary daily intake of protein should be approximately 0.8g/kg body weight in non-
dialysis-dependent patients. 
Angiotensin II receptor antagonists 
Candesartan 8–16 mg once daily 
Eprosartan 600–800 mg once daily 
Irbesartan 150–300 mg once daily 
Losartan 50–100 mg once daily 
Telmisartan 20–80 mg once daily 
Olmesartan 20–40 mg once daily 
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Treatment choice 
Diabetes complications compromise the kidneys’ filtration system, requiring the use of one 
of two techniques to purify the blood: 
•    haemodialysis 
•    peritoneal dialysis 
Haemodialysis 
Haemodialysis treatment does not cure kidney disease; it acts as a substitute kidney. 
Haemodialysis (cleaning the blood) uses a dialyzer (artificial kidney) to purify the blood of people 
suffering from severe renal (kidney) failure. The dialysis machine consists of a filter in which your 
blood circulates. The blood is mixed with a liquid called dialysate. The exchange between the two 
fluids (blood and dialysate) lets the blood eliminate certain substances (urea, creatinine, potassium, 
etc.) that were not filtered out by impaired kidneys. A system of tubing returns the blood to the 
body. At each treatment, a needle is inserted in the vein to allow the blood to flow through the tubes 
into the filter. Another needle is inserted to allow the blood to flow back into your body. The 
needles are removed at the end of each treatment run. 
The treatment usually takes 4 hours. Dialysis must be done 3 times per week to both purify 
the blood and remove excess liquid. Haemodialysis requires adhering to a fixed schedule and living 
close to a dialysis centre. 
Peritoneal dialysis 
Peritoneal dialysis is another way to purify the blood. Peritoneal dialysis requires self-care, 
which need a medical visit once a month. Peritoneal dialysis demands a strict aseptic technique, 
because any contamination can cause intra-abdominal infections. The principle behind this 
treatment method is to use the peritoneal membrane (the membrane surrounding the abdominal 
organs) as a filter. A small tube (catheter) is inserted into the abdomen, with one end extending 
outside the body. A liquid (usually 2 litres) resembling the dialysate used in haemodialysis is 
infused into the abdominal cavity, exposing the blood vessels in the peritoneum to the fluid. The 
peritoneum functions like the artificial membrane in a dialyzer. Excess water and waste (urea, 
creatinine, potassium, etc.) pass from the blood through the peritoneum into the dialysis fluid. 
Usually, the liquid is left in the abdomen for 4 hours and is then drained away using the catheter. It 
usually takes 30-45 minutes four times per day, 7 days per week. The choice between the two forms 
of treatment depends on several factors: medical, personal and social. In both cases, adaptation to 
this new way of life, which disrupts people`s lives because of its frequency and necessary time.  
Example of diagnosis of diabetic nephropathy: Diabetic nephropathy 4th degree.  
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2.1.3. Diabetic Retinopathy 
Pathogenesis  
Diabetic retinopathy (DR) development is caused by several factors, the most contributive of 
which is chronic hyperglycaemia, which results into tissue damage via multiple mechanisms. The 
two main changes in retinal structure are increased vessels` permeability and their occlusion. 
Occlusion of blood vessels leads to ischaemia, thus causing chronic retinal hypoxia. It stimulates 
production of growth factors, including vascular endothelial growth factor (VEGF). VEGF acts via 
protein kinase C to stimulate endothelial cell growth (causing new vessel formation) and increases 
vascular permeability (causing exudative damage).  
DR symptoms (based on complaints and objective examination) are characterized by: 
1. Blurred vision/double vision. 
2. Blindness in the late stages as a result of cataract caused by DR. 
3. Excessive tearing (due to dryness of the eye). 
4. Scotomas (presence of shapes or figures in the visual field due to oedema and exudates of the 
retina). 
5. Pain in the eyes (caused by occlusion of the retinal artery supplying the optic nerve). 
6. Oculomotor nerve palsy (rarely occurs). 
7. Glaucoma (due to increased intraocular pressure). 
NB: Usually DR is asymptomatic in the early stages. Signs of blindness or decreased vision 
are seen only in the late stages when macular oedema and vitreous haemorrhage takes place. All 
DM patients need eye check-ups every year and frequently depending on severity of DR. 
 
Diagnosing diabetic retinopathy student should pay attention to following signs:  
1. aneurysms or small haemorrhages, which appear as “dots&blots” signs; 
2. soft or hard exudates; 
3. IRMAs – abnormal branching of existing blood vessels; 
4. state of venules - their shape, size, presence of tortuosity; 
5. neovascularisation or abnormal new vessels; 
6. state of macula; 
7. retinal detachment; 
8. massive haemorrhages and their localisation. 
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Classification. A classification of diabetic retinopathy is based on prognosis for vision and 
indications for specialist referral. Microaneurysms, abnormalities of the veins, and small blot 
haemorrhages and exudates situated in the periphery will not interfere with vision unless they are 
associated with macular oedema in the perimacular or macular area. 
Table 12 – Diabetic retinopathy classification 
 
 
Findings Image Pathogenesis 
1. Nonproliferative stage 
Retinal 
microaneurysms 
 
Asymmetrical dilatation of 
weakened capillary wall primary 
to partial/total occlusion site. In 
most cases these are the earliest 
clinical abnormalities detected. 
They appear as tiny, discrete, 
circular, dark red spots near to, 
but apparently separate from, the 
retinal vessels.  
Hard exudates 
 
These are characteristic of DR. 
They vary in size from tiny 
specks to large confluent patches 
and tend to occur particularly in 
the perimacular area. They result 
from leakage of plasma and 
proteins from abnormal retinal 
capillaries and overlie areas of 
neuronal degeneration.  
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Soft exudates or 
cotton wool spots 
 
These are similar to those seen in 
hypertension, and occur 
particularly within five-disc 
diameters of the optic disc. They 
represent arteriolar occlusions 
causing retinal ischaemia and 
hence are a feature of pre-
proliferative diabetic retinopathy.  
 
Haemorrhages 
 
Occur in the deeper layers of the 
retina and hence are round and 
regular in shape and described as 
‘blot’ haemorrhages. May be 
difficult to differentiate from 
microaneurysms and the two are 
often grouped together as ‘dots 
and blots’. Superficial flame-
shaped haemorrhages may also 
occur, particularly if the patient is 
hypertensive.  
 
2. Preproliferative stage is characterised by the findings described above and: 
Macular oedema 
 
Focal or diffuse capillary leakage 
sometimes accompanied by 
cystoid macular changes. 
Ischaemic variant follows 
capillary closure and is associated 
with vision loss. 
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Blot 
haemorrhages 
 
As the weakening of the vessels` 
walls progresses, haemorrhages 
appear to be larger in size. 
Venous changes 
 
These include venous dilatation 
(an early feature probably 
representing increased blood 
flow), ‘beading’ (sausage-like 
changes in calibre) and increased 
tortuosity including ‘oxbow 
lakes’ or loops. These latter 
changes indicate widespread 
capillary non-perfusion and are a 
feature of advanced pre-
proliferative retinopathy. 
IRMAs 
 
Intraretinal microvascular 
abnormalities (IRMA) are dilated, 
tortuous capillaries which 
represent the remaining patent 
capillaries in an area where most 
have been occluded. 
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3. Proliferative stage 
Neovascularisation 
 
 
      May arise from the venous 
circulation on the optic disc or the 
retina in response to areas of 
ischaemic retina. The earliest 
appearance is that of fine tufts of 
delicate vessels forming arcades 
on the surface of the retina. As 
they grow, they may extend 
forward to the vitreous. They are 
fragile and leaky and are liable to 
rupture, causing haemorrhage 
which may be intraretinal, pre-
retinal (‘sub-hyaloid’) or into the 
vitreous.  
      Serous products leaking from 
these new vessel systems 
stimulate a connective tissue 
reaction, retinitis proliferans.  
Retinal detachment 
 
Neovascularisation is followed by 
fibrosis. Fibrous tissue causes 
retinal traction, which may result 
into tractional retinal detachment. 
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Image source https://www.glycosmedia.com/education/diabetic-retinopathy/ 
 
Example of diabetic retinopathy diagnosis 
1. Diabetic retinopathy, pre-proliferative stage. 
2. Diabetic retinopathy, proliferative stage. 
 
Rubeosis iridis 
 
Neovascularisation on the surface 
of iris. 
Vitreous 
haemorrhage 
 
Vitreous haemorrhage is the 
extravasation of blood into one of 
the several potential spaces 
formed within and around 
the vitreous body. 
Sub-hyaloid 
haemorrhage 
 
Accumulation of blood in areas of 
localized detachment of retina. 
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Treatment of diabetic retinopathy 
1. Control of blood glucose level (diet, exercise, medications and/or insulin) in the early stages of 
the non-proliferative stage of DR. 
2. Photocoagulation is the process of sealing the leaking weak vessels in the macular area and 
retina. It also reduces the stimuli for neovascularisation and stops bleeding. The options are 
focal, grid and panretinal laser photocoagulation. Focal and grid photocoagulation is used to treat 
diabetic macular oedema. Indications for panretinal photocoagulation are proliferative DR and 
some cases of non-proliferative DR. The potential complications of the procedure are reduced 
night vision and loss of peripheral sight. 
3. Glaucoma (abnormal intraocular pressure) and secondary cataract are the most common cause of 
blindness in patients with diabetes. OptoYag Slt&M Laser ophthalmic system appropriately 
generates a beam at 1064 nm Nd: YAG for performing selective laser trabeculoplasty (for the 
treatment of glaucoma) and 532 nm for performing secondary cataract surgery. 
4. ADA considers intravitreous injection of anti-vascular endothelial growth factor (anti-VEGF) to 
be as effective, as laser photocoagulation. Following drugs are currently used: 
a. Ranibizumab (Lucentis); 
b. Bevacizumab (Avastin); 
c. Aflibercept (Ailia). 
 
 
Figure 19 – Treatment with panretinal laser photocoagulation 
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Figure 21 – After photocoagulation 
 
Figure 22 – Preproliferative stage after laser  
photocoagulation 
 
Figure 20 – 
OptoYag&Slt M 
Laser 
 
 
 
 
Figure 24 – Treatment by Laser 
photocoagulation 
 
Figure 23 – Proliferative stage with retinal 
bleeding and neovascularization 
 
Figure 25 – Secondary cataract surgery 
procedures with ophthalmic laser system 
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2.2. Macroangiopathy 
 
Diabetic macroangiopathy could be all or either of the following: 
1. Cerebrovascular diseases. 
2. Cardiovascular diseases. 
3. Diabetic angiopathy of lower extremities. 
 
Risk factors of macroangiopathy 
 
Table 13 – Cardiovascular risk factors and target organ damage 
 
MAJOR RISK FACTORS 
Hypertension 
Age (older than 55 years for men, 65 years for women). 
Diabetes Mellitus  
Elevated LDL (or total) cholesterol, or low HDL cholesterol. 
Estimated GFR < 60ml/min. 
Family history of premature CVD (men < 55 years of age or women < 65 years of age). 
Microalbuminuria. 
Obesity  (BMI > 30 kg/m2). 
Physical inactivity. 
Tobacco usage, particularly cigarettes. 
TARGET ORGAN DAMAGE 
Heart 
 Left ventricular hypertrophy 
 Angina or prior myocardial infarction 
 Prior coronary revasculation 
 Heart failure 
Brain 
Stroke or transient ischaemic attack 
Dementia 
Peripheral arterial disease 
Chronic kidney disease 
Retinopathy 
BMI – body mass index, CKD – chronic kidney disease, CVD – cardiovascular disease, GFR – 
glomerular filtration rate, HDL – high density lipoproteins, LDL – low density lipoproteins. 
 Components of the metabolic syndrome. Reduced HDL and elevated triglycerides are 
components of the metabolic syndrome. Abdominal obesity is a component of metabolic syndrome. 
Ɨ Increased risk begins at approximately 55 and 65 years of age for men and women 
respectively. Adult treatment panel used earlier age cut points to suggest the need for earlier action. 
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Pathogenesis 
The main link of pathogenesis of macrovascular complications of DM is a promotion of 
atherosclerosis formation, which happens because of insulin resistance, obesity and 
hyperglycaemia. Excessive adipose tissue releases free fatty acids and mediators of inflammation. 
Increase in free fatty acids downregulates GLUT-4 expression, which leads to increased insulin 
resistance. It also leads to reduction in NO production, which can cause endothelial dysfunction.  
 Normal levels of insulin in the blood create antithrombotic state. Decrease in insulin 
levels or increasing insulin resistance lead to prothrombotic state, which also is a risk factor for 
macroangiopathy. 
 Another mechanism of organ damage is Möckerberg`s arteriosclerosis, which refers to 
mediacalcinosis of the vessels. Its origin is not fully understood, it can be a result of excessive 
calcium accumulation due to impaired protein synthesis.  
 
Table 14 – The main types of macroangiopathies 
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2.2.1. Cerebrovascular Diseases Caused by DM 
Mainly, it manifests as discirculatory encephalopathy with non-specific symptoms such as 
deterioration (gradual loss) of memory, dizziness, headaches, etc. 
Note that discirculatory encephalopathy is caused due to neuropathy as a result of 
microangiopathy. 
Patients with DM are also more likely to develop Alzheimer`s disease. 
Later clinical manifestations include ischaemic cerebral stroke, caused by atherosclerotic 
blockage of cerebral arteries. It results in brain infarction. 
 
2.2.2. Cardiovascular Diabetes Macroangiopathy 
Cardiovascular changes tend to occur earlier in patients with DM when compared with 
individuals of the same age. Frequency of myocardial infarction (MI) and mortality is higher in 
diabetics than that in nondiabetics of the same age. The prognosis is even worse if ketoacidosis or 
other complications of DM are present. Diabetic patients have more complications of MI 
(arrhythmias, cardiogenic shock and others) than nondiabetic ones. Often atypical (painless) forms 
can observe). 
 
Table 15 – Cardiovascular risk assessment in patients with diabetes according to ECS 
2019 guidelines 
Very high 
risk 
High risk 
Moderate 
risk 
 
b – Proteinuria, renal impairment (eGFR < 30 mL/min), left ventricular hypertrophy, or retinopathy. 
c – Age > 65 years, hypertension, dyslipidaemia, smoking, obesity. 
51 
 
Very high risk refers to 10-year risk of CVD > 10 %. 
High risk – 10-year risk of CVD 5–10 %. 
Moderate risk – 10-year risk of CVD < 5 %. 
 
Classification of arterial hypertension: 
1. According to aetiology: 
a) primary arterial hypertension (cause is usually unknown); 
b) secondary arterial hypertension (resulting from other secondary diseases like cardiovascular 
diseases, diabetes mellitus-nephropathy, chronic kidney diseases, etc.). 
2. According to clinical grades: 
a) grade 1 hypertension; 
b) grade 2 hypertension; 
c) grade 3 hypertension. 
 
Table 16 – Classification of arterial hypertension according to clinical grades 
Category SBP, mmHg DBP, mmHg 
Optimal < 120 And < 80* 
Normal 120–129* And/or 80–84 
High normal 130–139 And/or 85–89 
Grade 1 hypertension 
(Start antihypertensive drugs) 
140–159 And/or 90–99 
Grade 2 hypertension 160–179 And/or 100–109 
Grade 3 hypertension > 180 And/or > 110 
Isolated systolic hypertension > 140 And < 90 
*Target for patient with diabetes 
 
3. According to clinical stages (by joint national committee for the prevention, detection and 
treatment of arterial hypertension – 2009). JNC 7 category classification helps in determining 
treatment protocol: 
a) uncomplicated hypertension; 
b) asymptomatic hypertension; 
c) established hypertension. 
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Figure 26 – Australian cardiovascular risk charts 
 
Strategy of treatment of arterial hypertension in patient with diabetes 
1. Start antihypertensive drugs at > 140/90 mmHg. 
2. Target systolic blood pressure is 120–129 mmHg and 130–139 mmHg in older people 
(> 65 years). 
3. Target diastolic blood pressure is 70–79 mmHg. 
4. Start with ACE-inhibitor/ARB + CCB/thiazide diuretic (or thiazide-like diuretic). 
5. Do not combine ACE-inhibitors with ARB. 
See appendix D for preferred drugs and dosing. 
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2.2.3. Diabetic Angiopathy of Lower Extremities 
Diabetic angiopathy of lower extremities is diagnosed based on the clinical picture and 
instrumental methods. 
Clinical symptoms include: 
1. Decreased skin temperature of distal part of extremities in comparison to proximal part during 
palpation. 
2. Decreased or absent pulse in lower extremity arteries (Posterior tibial and Dorsalis Pedis 
arteries). 
3. Cyanotic or pale skin colour. 
4. Pain: manifested as intermittent claudication (pain when walking, causing patient to rest a little 
while to relief pain before continuing walking, due to vascular insufficiency). 
5. Trophic ulcers: located in areas not in contact with shoe pressure areas as well as at the terminal 
extremities of toes (because arterial insufficiency starts at the capillary levels which supply toes.) 
6. Gangrene of toes and extremities due to chronic untreated vascular insufficiency. 
 
Instrumental methods:  
 X-ray for bony destruction (Charcot or osteomyelitis; Menceberg’ arteriites). 
 Ankle-Brachial (ABI) and Toe-Brachial Indices, Segmental Pressure Examination. The ABI 
should be measured in both legs in all new patients with PAD of any severity to confirm the 
diagnosis of lower extremity PAD and establish a baseline. 
 Magnetic resonance angiography of the extremities is useful to diagnose anatomic location 
and degree of stenosis of PAD. 
 Contrast angiography provides detailed information about arterial anatomy and is 
recommended for evaluation of patients with lower extremity PAD when revascularization 
is contemplated. 
 Rheovasography is a graphical recording of impedance in a local area of study between 
electrodes with low-flux electric current. The procedure allows to provide a qualitative and 
quantitative assessment of vascular disorders, which determines the following integral 
rheovasographic indicators: 
1. Rheographic index (RI) indicates the relative value of pulse blood filling (N on foot=1,0 mom). 
2. The dicrotic index contains data about the tonic indices of the venous and signs of the venous 
stasis. 
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3. Diastolic index (DI) is the relation of the value of the amplitude on the level of dicrotic cog 
(additional wave) to the maximum amplitude of the rheographic wave and reflects mostly the 
condition of blood outflow from arteries to veins and tonus of the veins. 
4. The amplitude of the diastolic wave, which reflects the ratio of the arterial and venous component 
of the blood circulation. 
5. The velocity of fast blood flow reflects the blood filling of the large arteries (om/s). 
6. The rate of the slow blood flow characterizes the blood filling of the arteries of the medium and 
small diameter (om/s). 
7. Diastolic-systolic index demonstrates venous outflow. 
8. Asymmetry index (AI). 
 
 Continuous-wave Doppler ultrasound blood flow measurements are useful to provide an 
accurate assessment of lower extremity PAD location and severity, to follow lower 
extremity PAD progression, and to provide quantitative follow-up after revascularization 
procedures.  
 
 
Figure 27 – Continuous-wave Doppler ultrasound blood flow measurements 
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 Pulse oximetry measures the oxygen saturation of peripheral blood (SaO2) and is a 
screening tool to detect significant lower extremity arterial disease in patients with diabetes 
mellitus.  
 
 
 
 The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the 
systolic pressure at the arm. An ABI is calculated for each leg. 
 
 
Interpreting the Ankle Brachial Index 
1. Normal ABI ranges from 1.0–1.4.  
Pressure is normally higher in the ankle than the arm. 
2. Values above 1.4 suggest a noncompressible calcified vessel. 
3. In diabetic patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may 
be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff 
pressures. The persistence of a signal at a high pressure in these individuals results in an 
artifactually elevated blood pressure value. 
4. A value below 0.9 is considered diagnostic of PAD. 
5. A value 0.5–0.8 suggests moderate PAD. 
6. Values less than 0.5 suggests severe PAD and should be considered for revascularization. 
Figure 28 – Pulse oximeter 
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Figure 29 – Ischaemic foot examination 
 
Definition of peripheral occlusive disease of extremities 
According to the American College of Cardiology/American Heart Association (ACC/AHA) 
pathologies of the peripheral extremities fall under the following divisions: 
1. Asymptomatic: Absence of intermittent claudication symptoms. 
2. Claudication: Inadequate blood flow during exercise, causing pain during movement 
forcing patient to stop before continuing so that the limb is reperfused. 
3. Critical limb ischaemia: Compromise of blood flow to extremity, causing limb pain at rest. 
Patients often have ulcers or gangrene. 
4. Acute limb ischaemia: A sudden decrease in limb perfusion that threatens limb viability. 
Associated with the “5 Ps”: Pain, Paralysis, Paraesthesia, Pulselessness, Pallor. 
NB: The pulse is usually determined by feeling the dorsalis pedis artery and the posterior 
tibial artery. 
 
The classification of lower extremity macroangiopathy is based on the degree of progression 
of chronic peripheral ischemia to critical limb ischemia with intermittent claudication. 
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Table 17 – Classification of PAD after Fontane and Rutherford (comparison chart) 
Fontane Rutherford 
Stage Clinical Grade Category Clinical 
I Asymptomatic 0 0 Asymptomatic 
II a Mild claudication I 1 Mild claudication 
II b Moderate-severe claudication I 2 Moderate claudication 
I 3 Severe claudication 
III Ischaemic rest pain II 4 Ischaemic rest pain 
  III 5 Minor tissue loss 
IV Ulceration or gangrene IV 6 Ulceration or gangrene 
 
Table 18 – Classification of peripheral artery diseases by Leriche-Fontane-Pokrovsky 
Stage Explanation 
1st degree Pre-clinical stage 
Present all symptoms of vascularization 
disturbances (dry, scaly, cold, 
hyperkeratinized skin and absent pulse of 
feet) and chronic pain only during 
movement. Critical ischaemia is absent 
2nd degree. 
Intermittent 
claudication  
 
2A 
 
Claudication at a distance 
greater than 200 metres 
Present intermittent claudication (intensified 
pain during walking due to ischaemia 
forcing patient to stop and rest before 
continuing to walk to revascularize the leg) 
2B 
Claudication distance less than 
200 metres 
3rd degree Nocturnal and / or resting pain 
Pain present throughout the day and at night 
due to the development of severe critical 
ischaemia. 
NB: Need to differentiate this with 
polyneuropathic pain because the latter 
lacks prior intermittent claudication in 
history of the patient 
4th degree 
Necrosis (death of tissue) and/ or 
Gangrene in the limb 
Localized and/or spreading gangrene 
e * Source: Am Fam Phys 2001; 61:1027–1032, 1034. 
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2.3. Diabetic Foot Syndrome 
 
Diabetic foot syndrome is a polysymptomatic chronic complication of DM, characterized by 
both functional and organic damage of the lower extremities of diabetic patients due to both the 
disturbances of vascular and neurological properties of the lower extremities and infection 
complications. 
Classification of diabetic foot syndrome 
I. According to aetiopathogenesis: 
1. Neuropathic (neuropathic pain, paraesthesia, vibration loss and neuropathic ulcer 
formations). 
2. Ischaemic form (impairment of circulation). 
Manifested as pain (intermittent claudication), cyanotic skin colour, trophic ulcers on ends 
of toes and areas of feet not subjected to pressure with shoes. 
3. Neuroischaemic form. 
II. According to the depth of trophic ulcer (by Wagner). 
 
Table 19 – Classification of diabetic foot by Wagner 
 
Stage 0 There is no trophic ulcer. This stage includes all signs of an increased risk of feet 
ulceration: cold and dry skin, pain with walking (claudication), paraesthesia 
(numbness), paralysis (weakness), pulselessness (of dorsalis pedis and posterior 
tibial pulsus), pallor or cyanosis of distal extremities   
Stage 1 Presence superficial diabetic ulcer without infection 
 
Stage 2 Ulcer extension, i.e., involving ligament, tendon, joint capsule or fascia. 
Osteomyelitis is absent 
Stage 3 Deep ulcer with osteomyelitis 
 
Stage 4 Localized gangrene to toes or distal part of feet 
 
Stage 5 Extensive gangrene of foot (spreading gangrene) 
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Figure 30 – Lateral view of foot radiograph 
 
Figure 31 – Signs of diabetic foot syndrome at different stages of development 
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Table 20 – Differential diagnosis between neuropathic and ischaemic diabetic foot 
syndrome 
Clinical sign Neuropathic DF Ischaemic DF 
Foot deformities 
Clawed toes, possible high arch, 
possible Charcot deformities 
No specific deformities. 
Possible absent toes/forefoot 
from previous amputations 
Foot temperature/ 
foot pulse 
Warm, palpable pulse 
Cold or decreased temperature, 
pulse may be absent or reduced 
Skin colour Normal or red 
Pale or cyanotic. Pronounced 
redness when lowered 
(dependent rubor), blanching on 
elevation 
Skin condition 
Dry skin due to decreased 
sweating 
Thin, fragile and dry 
Ulcer location 
On the plantar aspects (forefoot 
80 %) of the foot/toes 
Distal/tips of the toes, heel, or 
margins of the foot 
Callus present 
Commonly seen on the weight-
bearing areas and is generally 
thick 
Not usually. If present, distal 
eschar or necrosis 
Ulcer 
characteristics 
Usually painless, with a 
“punched out” appearance 
(granulation or deeper base) 
surrounded by callus 
Painful, especially with necrosis 
or slough 
Sensation 
Reduced or absent sensation to 
touch, vibration, pain, and 
pressure 
Sensation may be present but 
decreased if there is associated 
neuropathy 
Ankle reflexes Usually not present Usually present 
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Figure 32 – Different stages of diabetic foot 
syndrome 
Figure 33 – Possible areas of vascular occlusion 
 of the lower extremities in diabetes mellitus 
EXAMPLE OF MAIKING DIAGNOSIS OF 
DIABETIC FOOT SYNDROME 
1. Diabetic foot syndrome stage 4, 
mixed form, bilateral lower extremity 
angiopathy stage 4, bilateral lower 
extremity sensory motor neuropathy. 
 
2. Diabetic foot syndrome stage 2, 
mixed form, bilateral distal lower 
extremity sensory neuropathy, 
bilateral lower extremity angiopathy 
stage 2b.         
Figure 34 – Lower extremity cyanosis 
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3. MANAGEMENT OF DIABETES MELLITUS 
 
Treatment of DM is carried out based on the type and degree of severity taking into 
consideration the state of compensation as well. The average hospitalization period is 10–14 
days to achieve a compensation state and the target values of the various diagnostic parameters 
as indicated in the tables below. 
1. Diet, exercise, self-education are often started as first line treatment protocols in 
early diagnosed cases of DM. 
2. Oral hypoglycaemic drugs are administered when diet control is ineffective in 
treating type 2 DM. 
3. Insulin is administered for treating T1DM and gestational DM and in the treatment 
of severe decompensated T2DM which is not responsive to oral hypoglycaemic 
medications and severe stages of chronic complications. 
Table 21 – Obesity stages and risk management 
 
Note: 
1. Treatment of DM should be individualized per patient since the therapeutic goal 
parameters to be achieved by any adopted method of treatment should be 
individualized for every patient. 
2. Determine therapeutic goal depending on the following parameters: 
 age (older patients have higher standards because of risks of hypoglycaemia amongst 
others); 
 patient’s self-motivation and willingness to use the adopted therapeutic measures; 
 cardiovascular risks (previous strokes, myocardial infarction, etc.); 
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 financial situation as well as social status of patient; 
 other histories of chronic diseases (which may render treatment of DM more difficult).  
3.1. Therapeutic Goals in Treating DM 
 
The therapeutic goals in treating DM: 
1. HbA1C goals: 
a) < 6 % – pregnant women; 
b) < 7 % (53 mmol/mol) – most nonpregnant adults and children; 
c) < 8 % (64 nmol/mol) – a history of severe hypoglycaemia, limited life expectancy, long-
standing diabetes, refractive to adequate treatment); 
2. Fasting* capillary plasma glucose, measured by patient with a glucometer (patient self-
monitoring of blood glucose) – 4.4–7.2 mmol/l (80–130 mg/dl); 
5.0–7.2 mmol/l for older adults; 
< 5.3 mmol/l for pregnant women. 
3. Peak postprandial capillary plasma glucose** – < 10 mmol/l (< 180 mg/dl) 
< 7.8 mmol/l for pregnant women.  
4. Bedtime glucose – 5.0–8.3 mmol/l (90–150 mg/dl) for older adults. 
5. Blood pressure: 
a) systolic – 120–129 mmHg and 130–139 mmHg in older people (> 65 years); 
b) diastolic – 70–79 mmHg. 
6. Lipids: 
a) total cholesterol – < 4.4 mmol/l; 
b) LDL cholesterol – < 2.6 mmol/l; 
c) HDL cholesterol – > 1.02 mmol/l; 
d) TAG – < 1.7 mmol/l. 
 [American Diabetes Association Standards of medical care in diabetes – 2015. Diabetes Care. 
2015; 38 Suppl1:S1–94.] 
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Table 22 – Lipid-lipoprotein goals in patients with DM 
Risk factor ATP III ADA IDF 
LDL cholesterol 
< 100 mg/dl (< 2.6 mmol/L) 
in individuals without overt 
CVD 
< 100 mg/dl (< 2.6 mmol/L) 
in individuals without overt 
CVD 
< 95 mg/dL 
< 70 mg/dl (1.8 mmol/L) 
optional or reasonable with 
overt CVD 
< 70 mg/dl (1.8 mmol/L) in 
individuals with overt CVD 
Non-HDL 
cholesterol 
< 130 mg/dl (< 2.6 mmol/L) 
if triglyceride > 200 mg/dl 
Not specified Not specified 
Triglycerides Not specified < 150 mg/dL < 200 mg/dL 
HDL 
cholesterol 
Not specified 
> 40 mg/dL in men 
> 50 mg/dl (1.3 mmol/L) in 
women 
> 39 mg/dL 
 
ADA – American Diabetes Association, ATP III – Adult Treatment Panel III, CVD – 
Cardiovascular disease; HDL – High density lipoprotein, IDF – International Diabetes 
Foundation, LDL – Low Density Lipoprotein 
 
3.2. Treatment of Type 1 DM 
 
Treatment of T1DM is by insulin therapy; however, diet, light aerobic physical and 
education of patient to be able to control signs of acute complications as well as managing DM are 
equally very important. 
 
   Diet 
1. Exclude from daily diet foods with glycaemic index (GI) of 70 to 100 %. Limit to products 
with GI of 70 to 65 % carbohydrates (sugar, honey, sweet pastries, jams, soft drinks). 
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2. Daily caloric value of carbohydrates (55 to 60 %), proteins (15 to 20 %), and fat (20 to 25 %) 
should be maintained. 
3. Restrict intake of saturated fatty acids to 10 % by substituting saturated fats with mono- and 
polyunsaturated fats (ratio 1:1:1), except for children of preschool age. 
4. After calculating the number of calories attributable to carbohydrates, determine the amount 
of bread units (BU).   
NB: (10 to12 g of carbohydrate food taken equals 1 BU).  
 
Daily physical exercise 
1. Physical activity increases insulin sensitivity and lowers blood glucose. 
2. The risk of hypoglycaemia increases during exercise and in the next 12–40 hours after a 
period of prolonged and intense physical exertion. 
3. For mild and moderate exercise lasting not more than 1 hour, it is required supplementation 
of carbohydrates before and after exercise (15 g of carbohydrate for every 40 minutes of 
sport). 
4. At moderate exercise lasting more than 1 hour and intense sport, a low dose of insulin is 
needed, which acts during and subsequent to 6–12 hours after exercise at 20–50 %. 
5. Blood glucose levels should be measured before, during and after exercise. 
6. During decompensation of diabetes, especially in the stage of ketoacidosis, physical 
exercise is contraindicated. 
7. Exercise should be regular but not traumatic. 
 
Insulin therapy 
It involves the use of either: 
1. Semisynthetic human genetically engineered insulin. 
2. Analogues of human insulin. 
NB: Animal (pork) insulin is no longer used. 
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Figure 37 – Insulin therapy regimens 
Figure 36 – Insulin pens Figure 35 – Insulin pump 
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Figure 38 – Insulin injection 
 
Mode of insulin administration 
In general, patients with T1DM require 50 % of their daily insulin as basal and 50 % as 
prandial. Total daily insulin requirements can be estimated based on weight, with typical doses 
ranging from 0.4 to 1.0 units/kg/day. Higher amounts are required during puberty, pregnancy, 
and illness. Typical starting dose is 0.5 units/kg/day for diabetes who are metabolically stable, 
with half administered as prandial insulin given to control blood glucose after meals and the 
other half as basal insulin to control glycemia in the periods between meal absorption.  
Typical multidose regimens for patients with T1DM combine premeal use of shorter-
acting insulins (3 times a day) with a longer-acting formulation (2 times a day for intermediate 
action and once a day for ultralong, usually at bedtime). The long-acting basal dose is titrated to 
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regulate overnight, fasting glucose. Postprandial glucose excursions are best controlled by a 
well-timed injection of prandial insulin. The optimal time to administer prandial insulin varies, 
based on the pharmacokinetics of the formulation, the premeal blood glucose level, and 
carbohydrate consumption.   
Proper insulin injection technique includes injecting into appropriate body areas, injection 
site rotation, appropriate care of injection sites to avoid infection or other complications, and 
avoidance of intramuscular (IM) insulin delivery. Exogenous-delivered insulin should be 
injected into subcutaneous tissue, not intramuscularly. IM injection being associated with 
frequent and unexplained hypoglycemia in several reports. Recommended sites for insulin 
injection include the abdomen, thigh, buttock, and upper arm. 
 
Table 23 – Classification of insulin according to duration of action 
Insulin Onset of action Peak action Duration 
Analogues of human 
insulin ultra-short action 
After 10 to 20 min Through 0.5 h 3 h 
Short-acting 30 min In 1.5 h From 5 to 8 h (av. 6 h) 
Intermediate duration From 1 to 1.5 h From 12 to 24 h From 12 to 24 h 
Pre-mixed Through 0.5 to 1 h Over 1.8 h From 12 to 24 h 
Pre-mixed human insulin 
analogue actions 
After 10 to 20 min In 1 to 4 h 15 to 24 h 
Analogue of human 
insulin ultra-long-acting 
After 1 h From 18 to 24 h Up to 24 h 
 
Daily insulin requirements 
The average daily requirement of insulin in patients with type 1 diabetes is 40 to 60 units. 
1. At onset of diabetes, from 0.5 to 0.6 IU/kg. 
2. Remission (“honeymoon”) – < 0.4 IU/kg. 
3. Prolonged diabetes with progressive chronic complications: from 0.7 to 0.8 IU/kg. 
4. Decompensation (puberty period, ketoacidosis): from 1.0 to 2.0 IU/kg. 
5. The dose for each patient depends on his individual needs and on the following parameters: 
body mass; diet, exercise; other comorbidities. 
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Correction of insulin dose should be made daily based on self-monitoring of 
blood glucose throughout the day.  
Pregnant women with diabetes, patients with diabetes with proliferative 
retinopathy, with decreased vision, children and adolescents should be provided with 
syringe-pens for insulin. 
 
Complications/side effects of insulin therapy 
1. Weight gain since insulin is an anabolic hormone. 
2. Risk of hypoglycaemia during course of treatment. 
3. Insulin resistance. 
4. Allergic reactions to insulin. 
 
Figure 39 – Insulin therapy 
Plan of future follow-up 
Recommendations to patients should be indicated in the epicrisis of the case history upon 
discharge from the hospital (dispensary follow-up).  
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Table 24 – Plan of diagnostic tests and consultations 
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3.3. Treatment of Type 2 DM 
 
The main cause of carbohydrate metabolism dysfunction in T2DM is mostly due to:  
1. Insulin resistance and relative insulin deficiency.  
2. A primary defect in insulin secretion with insulin resistance. 
The therapeutic goal in diabetes mellitus type 2 is preventing the risk of micro- and 
macrovascular complications. 
T2DM treatment involves: 
1. Diet. 
2. Exercise. 
3. Oral sugar decreasing drugs. 
4. Insulin therapy. 
5. Learning self-control and psychological support. 
6. Early treatment of complications and comorbidities (adequate control blood pressure, blood 
lipids). 
Note: Oral hypoglycaemic medications are used only in cases where: 
1. Diet and physical exercises have not attained the therapeutic goal for a long period of time. 
2. Laboratory parameters at diagnosis show high levels of HBA1c (> 7.5 %). 
3. Metformin is preferred drug of choice, but it is usually used in combination with other oral 
hypoglycaemic agents to achieve desired therapeutic goal. 
 
Diet 
Principles of feeding includes: 
1. Respecting of normal energy value (for obesity – foods with low energy value). 
2. Diet with restriction of saturated fats, cholesterol and carbohydrate (not more than one third of 
total carbohydrates). 
Diet № 9 and basic therapy for patients with type 2 DM is indicated with the main goal 
dedicated to weight loss in obese patients. 
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NB: Compliance with the diet often leads to normalization of metabolic disorders. When 
overweight, a low-caloric diet (< 1800 kilo calories) is recommended, which involves limiting the 
carbohydrate (candy, honey, sweet drinks) composition of food (% of energy value) as follows: 
1. Complex carbohydrates (pasta, cereals, potatoes, vegetables, fruits) 60 %. 
2. Saturated fats (milk, cheese, and animal fat) – 10 %. 
3. Polyunsaturated (margarine, vegetable oil) – 10 %; 
4. Proteins (meat, fish, eggs, milk, cheese) – up to 20 %. 
5. Inclusion in the diet foods rich in dietary fibers. 
6. Moderate use of non-caloric sweeteners. 
7. Limiting salt intake to 3 g/day in patients with arterial hypertension. 
8. Not more than 20 g/day intake of alcohol (in terms of pure alcohol) is indicated only in cases 
of absence of pancreatitis, severe neuropathy, and hypertriglyceridemia and alcohol 
dependence. 
 
NB: Compliance with the diet is an essential part of the treatment of type 2 diabetes 
regardless of any version of hypoglycaemic therapy. 
 
Physical activity 
Can improve the compensation of carbohydrate metabolism, reduce and maintain optimal 
body weight and reduce the risk of chronic heart disease (CHD). 
An individual approach, given the age of the patient, complications of diabetes, 
comorbidities (especially coronary heart disease, hypertension, autonomic and peripheral 
neuropathy, DR) is followed. 
 
NB: Except in cases of contraindications to sports, exercise of moderate intensity, a total 
of at least 2.5 hours per week, at least 3 times a week (with breaks to two consecutive days). 
 
To control blood glucose, because exercise can lead to hypoglycaemia, additional 
admission carbohydrate is done, provided that blood glucose level < 5.6 mmol/L before exercise. 
 
Prolonged or intense exercise may require dose adjustments of insulin or insulin 
secretion stimulators. During severe decompensation, exercise is not recommended. 
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Oral hypoglycaemic drugs 
Assigned in cases where dietary measures and increasing physical activity cannot 
achieve the goal of treatment in individual patients. 
Table 25 – Oral hypoglycaemic drugs effects 
Mechanism of action Advantages Disadvantages and 
potential side effects 
Biguanides 
- inhibit hepatic 
gluconeogenesis; 
- reduce insulin 
resistance of muscle 
and adipose tissues. 
- first line therapy; 
- effective; 
- weight loss; 
- no 
hypoglycaemia; 
- long history of 
safe using. 
- dyspepsia; 
- can`t be used at GFR <30 
ml/min; 
- may cause B12-
defficiancy. 
Sulfonylureas 
- stimulate insulin 
secretion. 
- effective; 
- long history of 
safe using. 
- hypoglycaemia; 
- weight gain; 
- may speed up destruction 
of beta-cells. 
Dipeptidyl peptidase-4 (DPP-4) inhibitors 
- suppress cleavage of 
endogenous incretins. 
- no weight gain; 
- well-tolerated; 
- preserve beta-
cells` function; 
- don`t cause 
hypoglycaemia. 
- dyspepsia; 
- immune reactions; 
- dangerous if heart failure 
risk is present. 
Glucagon-like peptide-1 (GLP-1) agonists 
- enhance glucose-
dependent insulin 
secretion; 
-  suppress glucagon 
secretion; 
- slow down gastric 
emptying. 
- weight loss; 
- no 
hypoglycaemia; 
- decrease 
glucagon levels; 
- reduce post-
prandial 
hyperglycaemia. 
- dyspepsia; 
- allergic reactions; 
- subcutaneous injection; 
- tachycardia; 
- should be avoided in 
patients with the history 
of pancreatitis or 
medullary carcinoma. 
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Table 25 continuation 
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors 
- increase glucose 
secretion with urine. 
-    weight loss; 
- reduce blood 
pressure; 
- no 
hypoglycaemia; 
- genitourinary infections; 
- polyuria; 
- hypotension; 
- increase low-density 
lipids. 
Acarbose 
- alpha-glucosidase 
inhibitor – reduce 
intestinal carbonate 
absorption. 
- no 
hypoglycaemia; 
- reduce post-
prandial 
hyperglycaemia. 
- diarrhoea; 
- dyspepsia; 
- less effective glycaemia 
control. 
Meglitinides 
- stimulate insulin 
secretion. 
- reduce post-
prandial 
hyperglycaemia. 
- hypoglycaemia; 
- weight gain. 
Thiazolidinediones (glitazones) 
- reduce insulin 
resistance of muscle 
and adipose tissue; 
- decrease glucose 
production by the 
liver. 
- increase high-
density lipids 
levels; 
- reduce 
triglycerides 
levels. 
- water retention; 
- bone fractures; 
- weight gain. 
 
 
 
Figure 40 – Oral hypoglycaemic drugs 
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Table 26 – Groups of drugs and mechanism of action 
Group of drugs Action mechanisms 
Sulfonylureas Stimulation of insulin secretion and recovery 
Biguanides Reduced glucose production by the liver, reducing insulin 
resistance of muscle and adipose tissue 
Meglitinides Stimulation of insulin secretion 
Thiazolidinedione 
(Glitazones) 
Reducing insulin resistance of muscle and adipose tissue, 
decrease glucose production by the liver 
Inhibitors of alpha glycosidase Reduced absorption of carbohydrates in the intestine 
Incretin analogues (GLP-1) Enhances glucose-dependent insulin secretion, suppresses 
glucagon secretion and gastric emptying 
Dipeptidyl peptidase-4 
(DPP-4) inhibitors 
Suppresses cleavage of endogenous incretins by DPP-4, 
thus elevating endogenous incretin levels. Effects are same 
as for incretin analogues 
Sodium-glucose cotransporter 
2 (SGLT-2) inhibitors 
Inhibit glucose reabsorption, causing increased glucose 
excretion with urine 
  
 
Table 27 – Oral hypoglycaemic agents 
Preparation Daily dose 
(mg) 
Multiplicity 
Reception 
(times/ day) 
Duration 
of action 
(h) 
Evidence Contraindication 
1 2 3 4 5 6 
SULFONYLUREAS Type 2 diabetes with 
predominant 
insufficient secretion of 
insulin (without 
obesity) in inefficiency 
diet and physical loads 
Type 1 diabetes 
ketoacidosis 
pregnancy and 
lactation; 
chronic renal 
insufficiency 
Gliclazide MR 30 to 120 1 24 
Micronized 
glibenclamide 
1.75 to 14 1.2 16 to 24 
Glibenclamide 2.5 to 20 1.2 16 to 24 
Glimepiride 1.8 1 24 
Glikvidon 30 to 120 1.3 8 to 12 
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Table 27 continuation 
1 2 3 4 5 6 
Glipizide 2.5 to 30 1.2 16 to 24 
  
Gliclazide 80 to 240 1.3 8 to 12 
MEGLITINIDES Type 2 DM 
predominant 
insufficient secretion of 
insulin (without obesity) 
and expressed 
hyperglycaemia 
after eating and at 
inefficiency diet and 
physical regimes 
Type 1 DM 
ketoacidosis; 
pregnancy and 
lactation; 
chronic renal 
insufficiency 
Repaglinide  
 
 
Nateglinide 
0.5 to 16 
 
 
120 to 480 
3 to 4 
 
 
3 to 4 
3 to 4 
 
 
3–4 
 
 
 
 
BIGUANIDES Type 2 diabetes with 
predominant 
insulin secretion 
insufficiency (with 
obesity) and 
hyperglycaemia 
fasting during 
inefficient diet and 
physical regimes 
1. Type 1 DM. 
2. Ketoacidosis. 
3. Pregnancy and 
lactation. 
4. Chronic heart. 
5. Hepatic and 
renal failure. 
6. Anaemia. 
7. Alcoholism. 
8. Advanced age 
Metformin 500 to 
3000 
3 8 
to12 
THIAZOLIDINEDIONE Type 2 DM prevalence 
of insulin secretion 
insufficiency after 
failure of diet and 
exercise 
1. Type 1 DM 
2. Ketoacidosis. 
3. Pregnancy and 
lactation. 
4. Pathologies of 
the liver  
5. Severe Cardiac 
and renal 
insufficiency 
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Table 27 continuation 
1 2 3 4 5 6 
INHIBITORS OF ALPHA-GLUCOSIDASE Type 2 DM with of 
hyperglycaemia 
prevalence 
ineffectiveness of 
diet and exercise 
1. Type 1 DM. 
2. Ketoacidosis. 
3. Pregnancy 
and lactation. 
4. Gastrointestina
l tract pathology 
Acarbose 150 to 
300 
3 6 to 8 
INCRETIN ANALOGUES (GLUCAGON-LIKE 
PEPTIDE – GLP-1) 
1. Enhances 
glucose-
dependent 
insulin secretion 
2. Suppresses 
elevated 
glucagon 
secretion and 
slows gastric 
emptying. 
3. Improves 
glycaemic 
control by 
reducing fasting 
and postprandial 
glucose 
concentrations in 
patients with 
type 2 diabetes 
1. Hypoglycaemia, 
when taken in 
conjunction with 
a sulfonylurea. 
 
2. GI disturbances 
nausea, 
vomiting, 
diarrhoea 
 
 
 
Exenatide  2 
(s/c) 
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            Table 27 continuation 
DIPEPTIDYL PEPTIDASE – 4 (DPP-4) 
INHIBITORS 
Blocks DPP-4 thus 
elevating the levels 
of endogenous 
incretins 
(endogenous GLP-1 
and GIP). Effects 
similar to Exenatide 
Respiratory 
disorders: 
headaches, 
nasopharyngitis, 
cold-like 
symptoms 
Sitagliptin (Januvia®)  100mg 1  
SODIUM-GLUCOSE COTRANSPORTER 2 
(SGLT-2) INHIBITORS 
Inhibit SGLT-2 in 
the proximal 
convoluted tube, 
therefore reducing 
glucose reabsorption 
and increasing 
glucose secretion 
with urine 
1. Urinary tract 
infections. 
2. Polyuria. 
3. Hypotonia. 
4. Increase in 
low-density 
lipids level 
Canagliflozin 100–300 1 24 
  Empagliflozin 10–25 1 24 
Dapagliflozin 5–10 1 24 
 
* Source: According to the recommendations of the International Diabetes Federation 
(IDF 19. Clinical Guidelines TasK Force. Global Guidelines for Type 2 Diabetes, 2019). 
 
1. Sulfonylureas are first line therapy is indicated for patients with a BMI of up to 30 kg/m2.  
2. Metformin is appointed as first line therapy in patients with type 2 diabetes with a BMI 
over 30 kg/m2, given the contraindications (class I, level of evidence A). Among anti-
hyperglycaemic drugs preference is given to those recommended drugs that can provide 
effective glycaemic control with minimal development hypoglycaemic conditions (class I, 
level of evidence A). 
3. When monotherapy fails to achieve the targets, a combination oral therapy medication with 
different mechanisms of action is administered. According to the consensus of the 
American diabetes association (ADA) and the European Association for the Study of 
Diabetes (EASD 2008), it is not recommended to prescribe rosiglitazone given the 
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increased risk of congestive heart failure, myocardial infarction, oedema and bone 
fractures. 
4. Recommended combinations of drugs (class PA, level of evidence B) sulfonylureas and 
meglitinides, sulfonylureas and thiazolidinediones (pioglitazone); meglitinides and 
biguanides, meglitinides and thiazolidinedione (pioglitazone), biguanides and 
thiazolidinedione (pioglitazone), acarbose combined with any hypoglycaemic drugs. 
 
The purpose of insulin therapy 
1. Fasting glucose < 6.5 mmol/l. 
2. Glucose 2 hours after meals < 9.0 mmol/l. 
NB: Before transfer to insulin therapy is necessary:  
1. To teach the patient self-monitoring techniques.  
2. Warn about the possibility of hypoglycaemia and how to fix it.  
3. See diet principles, variants of insulin therapy, combination therapy and adding 
insulin to oral glucose lowering drugs. 
4. Monotherapy: monoinsulinoterapy for reversal of oral hypoglycaemic drugs. 
 
Table 28 – Combination of insulin and oral glucose lowering drugs (OGLD)  
dose estimated 
Mode of insulin Starting 
dose 
Time input Dosage adjustment 
Insulin average 
duration 
8 to 12 U Bedtime Correction insulin dose (+2 to 
+4 U) every 2 to 3 days to 
achieve the goal:  
fasting glucose < 6.5 mmol/l, 
postprandial glycaemia 
< 9 mmol/l 
Insulin average 
duration 
8 to 12 U Before 
breakfast and 
before bedtime 
Insulin pre-mixed 
(30/70) once or twice 
a day 
8 to I2 U Before dinner 
or before 
breakfast and 
dinner 
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Table 29 – Monotherapy with OGLD with insulin cancellation dose estimated 
Scheme Type of insulin Starting out Time input Dosage adjustment 
1  Insulin mixed 
(30/70) 
8 to12 U Before breakfast Correction insulin dose (+2 to 
+4 U) every 2 to 3 days to 
achieve the goal: 
fasting glucose < 6.5 mmol/l, 
postprandial glycaemia 
< 9 mmol/l 
8 to 12 U Before dinner 
2  Insulin average 
duration 
8 to 12 U Before 
breakfast and 
before bedtime 
Short-acting 
insulin 
6 to 8 U Before meals 
  
For insulin patients type 2 diabetes drug of choice is genetically engineered human 
insulin (class PA, level of evidence B). Analogues of human insulin appointed in cases of 
intolerance to other insulin labile course DM with a penchant for severe hypoglycaemia. 
The average dose of insulin in patients with diabetes type 2 diabetes who require insulin 
is 50 units (class PA, level C). The dose for each patient depends on his individual needs and 
depends on the body mass, diet, physical activity, degree of insulin resistance and other 
comorbidities. 
 
Clinical observation of patients with type 2 diabetes without complications 
 
Indications for hospitalization of patients with type 2 diabetes: 
1. Acute decompensation of carbohydrate metabolism, requiring transfer to insulin. 
2. Severe ketoacidosis or coma (ketoacidotic, hyperosmolar, hypoglycaemic). 
3. Rapid progression of vascular complications of DM. 
 
NB: If signs of chronic complications including comorbidities, appearance of additional risk 
factors and questions about the frequency of inspection is solved individually. 
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Table 30 – Plan of diagnostic tests and consultations for T2DM 
Heading Frequency of inspection 
Self-monitoring of blood glucose (fasting 
and 2 hours after a meal) 
In the onset of the disease and 
decompensation – daily. Future depends on 
the type of hypoglycaemic therapy: the 
insulin – daily, on a diet and OGLD several 
times a week at different times of day 
HbA1c And once every 6 months (more often if 
indicated) 
Biochemical analysis of blood (total protein, 
cholesterol, triglycerides, bilirubin, AST, 
ALT, urea, creatinine, potassium, sodium, 
calcium) 
Once per year (no change) 
Total blood Once every year 
Urinalysis Once every year 
Microalbuminuria Twice a year since diagnosis of diabetes 
Blood pressure control Each time you visit the doctor 
ECG Once every year 
ECG stress test for the presence of > 2 risk 
factors 
Once every year 
Review feet Each time you visit the doctor 
Family doctor On a diet and OGLD in the direction of the 
family, on insulin monthly. 
Endocrinologist On a diet and OGLD in the direction of 
family 
Fluorography Once every year 
Optometrist, cardiologist Once every year 
Neurologist, surgeon, diabetic foot room Once a year. According to testimony – often 
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3.4 Treatment of acute complications of diabetes 
 
Acute complications of diabetes include: 
1. Hypoglycaemic coma. 
2. Diabetic ketoacidotic coma. 
3. Hyperosmolar coma. 
4. Lactacidemic coma. 
 
Table 31 – Glasgow coma scale 
Score 1 2 3 4 5 6 
Eyes Does not 
open 
eyes 
Opens eyes in 
response to 
painful stimuli 
Opens eyes 
in response to 
voice 
Opens eyes 
spontaneou
sly 
N/A N/A 
Verbal Makes 
no 
sounds 
Incomprehensive 
sounds 
Utters 
inappropriate 
words 
Confused, 
disoriented 
Oriented, 
converses 
normally 
N/A 
Motor Makes 
no 
moveme
nts 
Extension to 
painful stimuli 
Abnormal 
flexion to 
painful 
stimuli 
Flexion/ 
withdrawal 
to painful 
stimuli 
Localises 
painful 
stimuli 
Obeys 
commands 
 
Ketoacidotic coma 
Pathogenesis 
Diabetic ketoacidosis is a result of absolute insulin deficiency. Absence of insulin makes 
glucose transporting into insulin dependent tissues impossible. Cells reach a state of “energy 
hunger” as if there was no glucose in the blood. Endogenous glucose depots begin to be used 
under the action of stress hormones: glycogenolysis and gluconeogenesis are activated and lead 
to significant hyperglycaemia, but there is not enough insulin for glucose to reach the insulin-
dependent cells. In these conditions lipolysis is activated, and lipids break down to higher fatty 
acids to provide energy for cells. As a result, absolute insulin deficiency leads to uncontrolled 
excessive ketones production, severe electrolyte disturbances (K+, Na+, Cl–, Mg2+, Ca2+, PO4
3–) 
osmotic diuresis and dehydration. 
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Ketoacidosis is more common among patients with type 1 diabetes, especially if it is not 
diagnosed in time. Provoking factors are: acute or chronic infectious diseases, treatment 
noncompliance, mistakes in insulin injection technique, expired date for insulin use, unsuitable 
conditions for insulin storage, malfunction of insulin injection systems, poorly controlled 
glycaemia, surgical interventions or traumas, pregnancy, chronic therapy by insulin antagonists 
(glucocorticoids, diuretics). 
Clinical presentation 
Comatose state develops slowly – about 2–3 days or longer. Symptoms include thirst, 
polyuria, dryness of skin and mucous membranes, weakness, adynamia, headache, tachycardia, 
absence of appetite, nausea, vomiting, odour of acetone, loss of consciousness, Kussmaul 
breathing, hypothermia, hypotension, tachycardia, reduced tone of the eyeballs, miosis, acute 
abdominal syndrome.  
 Laboratory findings include hyperglycaemia > 30 mmol/l, hyperketonaemia, decompensated 
metabolic acidosis pH < 7.3, SB < 15 mEq/l, glucosuria, ketonuria, leucocytosis, proteinuria, 
hyperazotaemia, hypercreatinaemia. 
Treatment 
 Rehydration: 
o 0.9 % NaCl (if plasma Na+ level does not exceed 
150 mmol/l); 500 ml/hour for children, 500–
1 000 ml/hour for adults. 
o 0.45 % NaCl – if plasma Na+ is > 150 mmol/l. 
o 5 % glucose or 10% dextrose – if glycaemia is 
< 14 mmol/l; can be combined with 0.9 % NaCl.  
Volume of rehydration per hour must not 
exceed diuresis per hour by more than 500–
1 000 ml. Infusion should be stopped when the 
patient is conscious and able to drink. 
 
Time Volume of 
intravenous 
liquids 
1st hour 1 000 ml 
2nd hour 500 ml 
3rd hour 500 ml 
4th hour and later 300–500 
ml 
Table 32 – Rehydration 
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 Insulin: 
o low-dose regime; rapid-acting insulin; 
o 0.1 U/kg IV bolus; 
o continuous 0.1 U/kg/hour IV (diluted by 0.9 % NaCl 
solution); 
o target glycaemia of the first treatment day is 
14 mmol/l; 
o glycaemia must not be decreased faster, than 
5.5 mmol/l/hour. 
 Hypokalemia correction: 
start simultaneously with insulin, if pH > 7.1. 
7. Acidosis correction: 
o aetiotropic therapy is insulin; 
o administer NaHCO3 only recommended if severe acidosis pH < 6.9 or/and 
SB < 5 mmol/l in very limited quantities (1–1,5 mEq/kg) only after initial hydration, 
it must be diluted to avoid osmotic impact and slowly infused.   
8. Disseminated intravascular coagulation syndrome prophylaxis: 
heparin 2500-5000 U 4 times a day if plasma osmolality > 320 mOsm/l. 
9. After stabilization: 
o glycaemia < 10–12 mmol/l; 
o normal consciousness; 
o normal BP; 
o normal pH; 
proceed to subcutaneous rapid-acting insulin injections every 4–5 hours.  
K+ plasma level Infusion 
rapidity 
< 3.5 mmol/l 40 mmol/hour 
3.5–5.5 mmol/l 20 mmol/hour 
< 3.5 mmol/l not 
administrated 
Table 33 – Hypokalemia 
correction 
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Hyperosmolar coma 
Pathogenesis 
 It is usually provoked by exogenous dehydration accompanied by relative insulin deficiency. 
Hyperosmolar state is more common among people with type 2 diabetes. Provoking factors 
include vomiting, diarrhoea, bleeding, burns, diabetes insipidus, concomitant diseases. 
Clinical presentation 
Comatose state develops very slowly – about 10–12 days. Signs include: 
- dry skin and mucous membranes;  
- polyuria (later oliguria and anuria possible);  
- progressive weakness;  
- adynamia;  
- reduced skin turgor; 
- reduced tone of the eyeballs;  
- malaise;  
- acetone odour is absent;  
- Kussmaul breathing is absent;  
- polymorphic neurological symptoms (speech disturbances, nystagmus, paresis, paralysis, 
convulsions, etc.). 
It is important to carry out a differential diagnosis with brain oedema to avoid misdiagnosis 
and administration of diuretics instead of rehydration. 
Laboratory findings include prominent hyperglycaemia, > 30–50 mmol/l; hyperosmolarity, 
> 310 mOsm/l; no ketonemia; hypernatremia; massive glucosuria; no acetonuria; no acidosis, 
pH > 7.3; SB > 15 mEq/l. 
Treatment 
1. Rehydration: 
a. 0.45 % NaCl solution if plasma Na+ 145–165 mmol/l; 
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b. 5 % glucose solution if plasma Na+ > 165 mmol/l; Na-containing solutions are contraindicated; 
c. 0.9 % NaCl solution if plasma Na+ < 145 mmol/l. 
2. Insulin – same principles, as in DKA treatment.  
Lactacidemic coma 
Pathogenesis 
 Provoking factors include: 
- states, that promote lactate production: decompensated diabetes, DKA, biguanides; 
- states, accompanied by reduced lactate clearance: liver parenchyma destruction, alcohol abuse; 
- states, which combine increased production and reduced clearance of lactate; 
- tissue hypoxia: chronic cardiovascular failure, ischemic heart disease; 
- combination of several factors: acute stress, age >65 years, late stages of diabetes 
complications, oncological processes; 
Table 34 – Classification of lactacidemic states 
Associated with tissue 
hypoxia (type A) 
Not associated with tissue hypoxia 
Type B1 Type B2 Type B3 
Cardiogenic shock Protractedly and 
formidably 
decompensated 
diabetes  
Biguanides Type 1 glycogen 
storage disease (von 
Gierke disease, when 
the body cannot break 
down glycogen) 
Endotoxic, 
hypovolemic shock, 
CO-poisoning 
Renal or/and liver 
dysfunction 
IV glucose, fructose, 
sorbitol, xylitol 
Methylmalonic 
acidaemia 
Anaemia Oncological processes Salicylates 
Pheochromocytoma Haemoblastosis Methanol, ethanol 
Epilepsy Infectious diseases Cyanides 
 
87 
 
Clinical presentation: 
- muscle pain; 
- heartache, which does not reduce after antianginal medication administration; 
- stomach-ache; 
- headache; 
- weakness, malaise; 
- nausea, vomiting; 
- low blood pressure; 
- drowsiness, which proceeds into stupor and coma; 
- dyspnoea, later – Kussmaul breathing. 
Laboratory findings include: hyperlactataemia; decompensated metabolic acidosis; anion gap 
> 15 mEq/l (Na+ – (HCO3– + Cl–); HCO3– < 18 mEq/l; mild hyperglycaemia; pH < 7.3; no 
ketonemia; plasma lactate > 5 mmol/l. 
Treatment 
1. Lactate synthesis inhibition: 
a) rapid-acting insulin 2–4 U/hour IV diluted by 5 % glucose 100–250 ml/hour. 
2. Lactate excess removing: 
a) haemodialysis with a lactate-free dialyzer. 
3. Acid-base balance restoration: 
a) artificial hyperventilation for excess CO2 removal; 
b) IV NaHCO3 solution, not more, then 50 ml 8,5 % once. 
4. Treatment of shock and hypovolemia. 
Hypoglycaemia 
Pathogenesis 
 Excess amount of insulin in the organism relatively to carbohydrates intake.  
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 Classification: 
1. Mild hypoglycaemia – patient can self-diagnose and self-
medicate with oral carbohydrates intake. 
2. Moderate hypoglycaemia – patient can`t help himself, but 
oral carbohydrates intake can resolve this state. 
3. Severe hypoglycaemia – patient is half-conscious, needs 
parenteral carbohydrate therapy. 
4. Asymptomatic “biochemical hypoglycaemia”. 
Clinical presentation and laboratory findings: 
1) glycaemia < 2.8 mmol/l; 
2) adrenergic symptoms; 
3) neuroglycopenic symptoms. 
Treatment 
1. Mild hypoglycaemia: 
simple carbohydrates intake: 1–2 bread units (4–5 sugar cubes, 
dissolved in water), honey, jam, 200 ml of fruit juice or 100 ml 
of lemonade (Pepsi, cola, Fanta) or 4–5 tablets of glucose. 
2. Severe hypoglycaemia: 
a) IV bolus 40 % glucose solution 20–100 ml; 
b) 1,0 ml glucagon SC or IM; 
c) if the patient is still unconscious – 5 % glucose solution IV continuous infusion, 
transportation to intensive care unit.  
Adrenergic 
symptoms 
Neuroglycope
nic symptoms 
Adrenergic 
symptoms 
Neuroglycope
nic symptoms 
Adrenergic 
symptoms 
Neuroglycope
nic symptoms 
Tachycardia Malaise 
Mydriasis Headache 
Tremor Dizziness 
Pallor Disorientation 
Sweating Fear 
Nausea Paraesthesia 
Hunger 
 
Speech, sight, 
coordination 
disturbances 
Aggressive 
behaviour 
Cramps 
Anxiety Amnesia 
 
 
 
 
Table 35 – Hypoglycaemia 
sy pto s 
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Education of patients with diabetes 
 
1. Education and psychological support for patients with diabetes is the integrating component 
of the treatment process of DM that provides patients the knowledge, skills and motivation 
to achieve a specific therapeutic purpose. 
2. Educational activities are carried out with all patients with diabetes since its discovery and 
during its course. The purpose and objectives of training should be specified in accordance 
with the actual condition of the patient. 
3. Training is carried out both individually and in groups of patients (type 1 DM, type 2 DM 
without insulin; type 2 DM on insulin, etc.). Using the developed programs. 
4. Base training is a hospital or clinic with the release of a separate room with the necessary 
equipment (school board, glucometers, test strips, drug samples and tools insulin, visual 
aids, etc.). 
5. Education and psychological support to patients carried out by specially trained health care 
workers: endocrinologists, nurses, involving a dietician and a medical psychologist. 
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APPENDICES 
APPENDIX A 
(obligatory) 
SUMMARY OF THE CLINICAL METHODOLOGY 
 
1. Investigation of complaints through patient interviews and physical examination. 
2. Establishment of preliminary diagnosis and diagnoses of complications. 
3. Select an array of diagnostic tests (integrating clinical data with laboratory and 
instrumental data). 
4. Differential diagnosis of the basic diagnosis. 
5. Establishment of clinical diagnosis. 
6. Patient management. 
7. Epicrisis with further recommendations. 
 
PLAN OF PATIENT CASE HISTORY 
 
PASSPORT DETAILS: 
Name _________________________ 
Surname _______________________ 
Date of birth _________, age _______ 
Home address ___________________ 
Education: _________ 
Marital status: ___________________ 
Work record: ______ 
Date of admission to the hospital ______ 
Institution which has directed patient to the hospital ____ 
Pre-admission diagnosis ___________________________ 
Patient’s department _____________________________ 
 
 Complaints. 
 Anamnesis Morbi. 
 Anamnesis Vitae. 
Appendix A continuation 
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 Physical examination of patient. 
 Preliminary diagnosis of patient. 
(Based on the information obtained from complaints, anamnesis morbi, anamnesis vitae, and 
physical examination of the patient). 
 Additional methods of routine diagnostic investigations to confirm clinical diagnosis: 
– laboratory (stool, glycaemic level, general urine analysis, biochemical urine analysis, 
general blood analysis, biochemical blood analysis); 
– instrumental methods (ECG, etc.). 
 Analysis of all obtained data from the patient’s complaints till the additional investigative 
diagnostic methods and differential diagnosis. 
 Clinical diagnosis and its confirmation. 
 General management plan: 
– lifestyle modifications; 
– diet; 
– principles of treatment (pharmacological, surgical, physiotherapeutic methods, etc.) and 
prescription of medications. 
 Daily evaluation of patient (daily dairy). At least 2 daily evaluations. 
 Epicrisis: indicate here concise (short and detailed) information of patient during time of 
hospitalization and during time of patient discharge. 
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APPENDIX B 
(obligatory) 
 
PHYSICAL EXAMINATION TECHNIQUES (PATIENT CASE HISTORY GUIDELINES) 
 
Patient Interview Technique 
 
The written history of an illness should embody all the facts of medical significance in the 
life of the patient. If the history is recorded in chronological order, recent events should be given the 
most attention. Likewise, if a problem-oriented approach is used, the problems that are clinically 
dominant should be listed first. Ideally, the narration of symptoms or problems should be in the 
patient’s own words. The health professional must be alert to the possibility that any event related 
by the patient however trivial, or apparently remote, may be the key to the solution of the medical 
problem. 
An informative history is more than orderly listing of symptoms. Something is always 
gained by listening to patients and noting the way in which they describe their symptoms. 
Disturbance of voice, facial expression and attitude betray important clues to the meaning of the 
symptoms to the patient. In listening to the history, the interviewer discovers not only something 
about the disease but also something about the patient. Listening is the key to proper clinical 
history. 
Patients cannot be tied down to an orderly sequence of history taking. They must be allowed 
as far as possible, to tell their story in their own words and in their own way. Only when they have 
done this should they be asked to enlarge on what appear to be the more important aspects of the 
story and only after that should specific questions asked. 
Make it clear from your stance, gestures and expressions that the patient has your whole 
attention and that you will not be shocked or angered by anything he/she says. Gazing out of the 
window or continually writing notes will put off the patient. Never underestimate the power of 
communication inherent in touching your patient. If a patient does make one angry or confused, it is 
best to recognize this and try starting the interview afresh by saying: “I haven’t quite got this clear 
yet; let’s go over it again so that I get it right.” A patient goes to a health institution, perhaps for the 
first time in his life, on the other hand with apprehension and suspicion and with the intention of 
unfolding his life story to the health professional that he regards as his best confidant and whom he 
expects to respect his human dignity. Patients often want to talk and explain their problem and, by  
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Appendix B continuation 
 
doing so, get some peace of mind. It should also be remembered that the patient is a person not 
simply a case. 
Avoid careless remarks that may hurt the feelings of your patient and thereby jeopardize the 
friendly communication you would like to establish between your patient and yourself. Besides, 
remember that any emotional upset may change the course of the illness of the patient. So, you 
should try to alleviate anxieties by repeated reassurance. 
It is also important to note that the medical and paramedical personnel should respect the 
professional secrecy so much expected of them. Thus, a medical record is strictly the property of the 
medical staff looking after the patient and should not be exposed to anyone outside the staff, nor 
should the contents be told to others at any time. 
 
SAMPLE QUESTIONS FOR PATIENTS 
Anamnesis Morbi: 
 
1. The onset of disease, what was his/her fasting and postprandial glycaemic level when first 
diagnosed DM? 
2. The duration of the diseases. 
3. What preceded the disease?  
4. The development of disease. 
5. The result of previous additional methods of investigation, his/her fasting and postprandial 
glycaemic level (if they were present). 
6. The previous treatment (if it was present). Ask about the type of insulin being used, delivery 
system (pump vs. injections), dose, and frequency. Also ask about oral hypoglycaemic 
agents taken, doses and frequency. 
7. The effect of previous treatment (if it was present): Is the patient’s diabetes generally well 
controlled? Does the patient self-monitor his or her blood glucose levels? Does the patient 
have severe hypoglycaemic reactions? Has the patient had episodes of unexplained 
hypoglycaemia? If so, when, how often, and how does the patient treat these episodes? 
8. Regarding microvascular complications: Microvascular complications, such as retinopathy 
and nephropathy, should be considered as well. Consider the following questions: 
 When lastly did the patient see an ophthalmologist? What were the results? 
 Does the patient have known kidney disease? 
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 What were the dates and results of the last measurements of urine protein and serum 
creatinine levels? 
9. Regarding macrovascular complications: Macrovascular complications should be explored. 
Questions should include the following: 
 Does the patient have hypertension? What medications are taken? 
 Has the patient had a stroke or transient ischaemic attack? 
 What are the patient’s most recent cholesterol levels? 
 Is the patient taking cholesterol-lowering medication? 
10. Regarding Neuropathy complications: Potential neuropathy should be taken into account. 
Ask whether the patient has a history of neuropathy or symptoms of peripheral neuropathy 
or whether autonomic neuropathy is present (including impotence if the patient is male). 
11. Regarding Foot disease complications: 
 The possibility of foot disease should be addressed. Inquire as to whether the patient has 
a history of foot ulcers or amputations or whether any foot ulcers are present and when (if 
it was presence)? 
 Are frequent infections a problem? At what site? 
12. The reason for present hospitalization? 
 
NB: Main points that should be noted in the section of Anamnesis Morbi (meaning the events 
during the clinical course of the disease) include: 
 
1. Patients with poorly controlled blood glucose levels heal more slowly and are at increased risk 
for infection and other complications. 
2. Patients with type 1 DM are treated with insulin, type 2 DM are treated by oral hypoglycaemic 
agents and only in some indicated cases of treatment resistance with insulin. 
3. If the patient has episodes of severe hypoglycaemia and therefore is at risk for losing 
consciousness, this possibility must be addressed. 
4. Note the frequency and range of glucose level values at each time of day which was monitored 
by the patient. 
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Anamnesis Vitae:  
1. Allergic anamnesis to any foods of foreign substances as well as medications including insulin. 
2. Family history of DM, obesity, hypertension, cardiac disorders, strokes, hereditary diseases 
amongst immediate relatives whether alive or deceased. 
3. Social habits which worsen DM complications (e.g., alcoholism and smoking). 
4. Professional hazards or possible exposure to environmental factors that may cause or worsen 
DM. 
5. Other pathologies or health related problems: 
– big foetus of weight > 4200 g; 
– history of vascular diseases (varicose veins, obliterating endarteritis, etc.); 
– cardiovascular disorders (hypertension, myocardial infarction, cerebrovascular stroke, etc.); 
– previous surgeries prior to admission (types and extend of surgeries). 
Table 36 – Diagnostic algorithm 
Suspected diabetes - Presence of the main triad of symptoms: polyuria, 
polydipsia, weight loss at the onset of DM 
- The presence of diabetes in relatives. 
See page 9 
Verification of the basic 
diagnosis of DM 
1. FPG > 6.1 mmol/l 
2. PPG > 11.1 mmol/l 
See page 11 
Type of DM 1. Anamnesis gathering to determine the conditions of 
DM onset (age, weight loss, DKA) and previous 
laboratory data. Ex.: DM type 1 – in childhood, DM 
type 2 – in adults). 
2. Laboratory data: 
- serum C-peptide and insulin determination (DM type 1 
– Low, DM type 2 – High); 
- determination of GADA, IAA and ICA (DM type 1 – 
“+”). 
See page 13 
Degree of DM severity According to the chronic complication stages and the 
treatment needed for glycaemia compensation. 
See page 16 
State of DM 
compensation/decompensation 
1. Presence or absence of main triad of DM. If present, 
then state is said to be decompensation. If absent, then 
compensation. 
2. According to laboratory data obtained from fasting and 
postprandial glycaemic levels, and level of glycated 
haemoglobin in blood (HbA1c). See page 18 
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Table 37 – Chronic complications of DM diagnosis algorithm 
Diabetic retinopathy Signs of blindness or decreased vision. The stage is 
evaluated by ophthalmologist via retinoscopy examination. 
See page 40 
Diabetic neuropathy Neuropathy in anamnesis or symptoms of peripheral 
neuropathy or whether autonomic neuropathy is present. 
Neurological examination of vibration, tactile, temperature, 
pain sensitivity.  Presence of paraesthesias, abnormal 
sensations, pain in extremities. See page 19 
Diabetic nephropathy Stage is evaluated according to microalbuminuria values, 
eGFR, creatinine to albumin ratio. See page 33 
Diabetic angiopathy of the lower 
extremities 
She is based on the clinical complaints (decreased skin 
temperature, pulse, cyanotic skin colour, pain, trophic 
ulcers, gangrene) and instrumental methods. The stage is 
evaluated by according to the depth of trophic ulcer. The 
form is evaluated by according to aetiopathogenesis. See 
page 53 
Cerebrovascular angiopathy It manifests as discirculatory encephalopathy (deterioration 
of memory, dizziness, headaches, etc), ischaemic cerebral 
stroke. See page 50 
Cardiovascular diseases Evaluate patient`s risk for cardiovascular accidents, 
manage comorbid cardiovascular states. See page 50 
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RESULTS OF ADDITIONAL METHODS OF EXAMINATION 
 
Table 38 – Routine blood analysis (clinical blood analysis) 
Test Normal Date Remark 
Hb 
120 to 140 g/L for women 
130 to 160 g/l for men 
  
Erythrocytes 
3.5 to 5.5x1012/L for 
women 
4.2 to 6.9x1012/L for men 
  
Leucocytes 3.5 to 9x109/L   
Eosinophil 1 to 7 % of WBC   
Basophil 0 to 2 % of WBC   
Neutrophilic 
band form 
3 to 5 % of WBC   
Juvenile    
Segmented 45 to 70 % of WBC   
Lymphocytes 16 to 40 % of WBC   
Monocytes 3 to 10 % of WBC   
Haemoglobin 
120 to 140 g/l for woman 
130 to 160 g/l for men 
  
Thrombocytes 150 to 320x109 cells/l   
ESR 
5 to 15 mm/h for women 
3 to 12 mm/h for men 
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Table 39 – Biochemical analysis of blood 
Test Normal Date Remark 
Total Protein 60 to 80 g/L   
Albumin 35 to 55 g/L   
Bilirubi
n 
Total 5 to 20 μmol/L   
Direct 0 to 5 μmol/L   
Calcium 2.25 to 2.75 mmol/L   
Potassium 3.5 to 5.1 mmol/L   
Alanine 
aminotransaminas
e (ALT) 
5 to 56 IU/L 
  
Aspartate 
aminotransaminas
e (AST) 
Male: 8 to 40 IU/L 
Female: 6 to 34 IU/L 
  
Glucose 
(capillary plasma) 
3.3 to 5.5 mmol/L. 
80 to 100 mg/dL 
  
Urea 
1.2 to 7.0 mmol/dL 
7 to 21 mg/dL 
  
Creatinine 
Male: 0.7 to 1.3 mg/dL 
(60 to 118 μmol/L). 
Female: 0.6 to 1.1 mg/dL 
(50 to 98 μmol/L) 
  
BUN ratio 5 to 35   
Osmolarity 290 to 320 mOsm/l   
LDL 2.0 to 5.1 mmol/L   
HDL 1.0 to 2.2 mmol/L   
Cholesterol < 5.17 mmol/L   
Atherogenic Index 2 to 4.5   
TAG < 2.3 mmol/L   
HbA1c 4 to 6   
C-peptide 1.1 to 4.4 ng/ml   
99 
 
 
Appendix C continuation 
 
Table 40 – Glycaemic profile 
Time 
Glucose levels 
Date Date Date Date 
7:00 (fasting)     
10:00 (2 hours after meal)     
14:00 (2 hours after meal)     
16:00 (2 hours after meal)     
22:00 (2 hours after meal)     
4:00     
 
Table 41 – General urine analysis  
Test Normal Date Remark 
Amount 100 ml   
Specific 
Gravity 
1.003 to 1.030 
  
Osmolality 400 mOsm/l   
pH 5 to 7   
Protein 0 to 20 mg/dL   
Glucose absent   
Potassium 40 to 90 mmol/24 h   
Ketone bodies absent   
Epithelium absent   
Leucocytes 0 to 2   
Erythrocytes 
0 to 3 (male) 
0 to 6 cells (female) 
  
Casts 0   
Crystals 0   
Mucous 0   
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Urinal examination by Nechiporenko 
Leucocytes = 2x103 /l 
Erythrocytes = 1x103/l 
  
 24-hour urine test 
24-hour urine protein = ______________mg/day. 
 
 Reberg`s test 
Normal GFR, glomerular filtration rate = 80 to 120 ml/min. 
 
GFR (ml/min) = {urine creatinine (mmol/24 hours) * (diuresis per min (ml/min))}/blood 
creatinine(mmol/l) 
 
Estimated GFR is adjusted to the body area (m2) 
 
eGFR (ml/min/1.73m2) = {1.73 * urine creatinine (mmol/24 hours) * (diuresis per min 
(ml/min))}/(blood creatinine(mmol/l)*body area (m2)) 
 
Inulin clearance test 
This is one of the tests to determine the patient`s GFR. A fluid containing inulin is administrated 
and then urine samples are collected over several hours. The volumes of samples are noted and the 
amount of inulin in each sample is calculated. It is not routinely ordered. 
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Table 42 – Oral antihypertensive drugs 
Class Drug (trade name) 
Usual dose 
range 
(mg/day) 
Usual daily 
frequency 
1 2 3 4 
Alpha-1 blockers Doxazosin (Cardura) 
Prazosin (Minipress Ɨ)) 
Terazosin (Hetzin) 
1–16 
2–20 
1–20 
1 
2–3 
1–2 
Central alpha-2 
agonists and other 
centrally acting 
drugs 
Clonidine (Catapres Ɨ)) 
Clonidine patch (Catapres – TTS) 
Methyldopa (Aldormet Ɨ)) 
Reserpine (generic) 
Guanfacine (Tenex Ɨ)) 
0.1–0.8 
0.1–0.3 
250–1000 
0.1–0.25 
0.5–2 
2 
1 weekly 
2 
1 
1 
Direct vasodilators Hydralazine (Apresoline Ɨ)) 
Minoxidil (Loniten Ɨ)) 
25–100 
2.5–80 
1 
1–2 
ACEIs Benazepril (LotensinƗ) 
Capropril (CapotenƗ) 
Enalapril (VasotecƗ) 
Fosinopril (Monopril) 
Lisinopril (Prinivil, ZestrilƗ) 
Moexipril (Univasc) 
Peridopril (Aceon) 
Ramipril (Altace) 
Trandolapril (Mavik) 
10–40 
25–100 
5–40 
10–40 
10–40 
7.5–30 
4–8 
2.5–20 
1–4 
1 
2 
1–2 
1 
1 
1 
1 
1 
1 
Angiotensin II 
antagonists 
Candesartan (Atacand) 
Eprosartan (Teveten) 
Irbesartan (Avapro) 
Lorsartan (Cozaar) 
Olmesartan (Benicar) 
Telmisartan (Micardis) 
Valsartan (Diovan) 
8 – 32 
400 – 800 
150 – 300 
25 – 100 
20 – 40 
20 – 80 
80 – 320 
1 
1–2 
1 
1–2 
1 
1 
1–2 
CCBs – non-
dihydropyridines 
Diltiazem extended release (Cardizem CD, 
Dilacor XR, TiazacƗ)) 
Diltiazem extended release (Cardizem LA) 
Verapamil immediate release (Calan, IsoptinƗ) 
Verapamil long acting (Calan SR, Isoptin SRƗ) 
Verapamil – (Coer, Covera HS, Verelan PM) 
180 – 420 
120 – 540 
80 – 320 
120–480 
120–360 
1 
1 
2 
1–2 
1 
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1 2 3 4 
CCBs – 
Dihydropyridines 
Amilodipine (Norvasc) 
Felodipine (Plendil) 
Isradipine (Dynacirc CR) 
Nicardipine sustained release (CArdene SR) 
Nifedipine long – acting (Adalat CC, Procardia 
XL) 
Nisoldipine (Sular) 
2.5–10 
2.5–20 
2.5–10 
60–120 
30–60 
10–40 
1 
1 
2 
2 
1 
1 
Thiazide diuretics Chlorothiazide (Diuril)  
Chlorothialidone (generic) 
Hydrochlorothiazide (Microzide, 
HydroDIURIL) 
Polythiazide (Renese) 
Indapamide (LazolƗ) 
Metolazone (Mylorox) 
Metolazone (Zaroxolyn) 
125–500 
12.5–25 
12.5–50 
2–4 
1.25–2.5 
0.5–1.0 
2.5–5 
1–2 
1 
1 
1 
1 
1 
1 
Loop diuretics Bumetanide (BumexƗ) 
Furosemide (LasixƗ) 
Torsemide (DemadexƗ) 
0.5–2 
20–80 
2.5–10 
2 
2 
1 
Potassium sparing 
diuretics 
Amiloride (MidamorƗ) 
Triamterene (Dyrenium) 
5–10 
50–100 
1–2 
1–2 
Aldosterone 
receptor blockers 
Epelerone (Inspra) 
Spironolactone (AldactoneƗ) 
50–100 
25–50 
1 
1 
BBs Atenolol (TenorminƗ) 
Etaxolol (KerloneƗ) 
Bisoprolol (ZebetaƗ) 
Metoprolol (LopressorƗ) 
Metoprolol extended release (Toprol XL) 
Nadolol (CorgardƗ) 
Propanolol (InderalƗ) 
Propanolol long acting (Inderal LAƗ) 
Timolol (BlocardrenƗ) 
25–100 
5–20 
2.5–10 
50–100 
50–100 
40–120 
40–160 
60–180 
20–40 
1 
1 
1 
1–2 
1 
1 
2 
1 
2 
BBs with intrinsic 
sympathomimetic 
activity 
Acebutol (SectralƗ) 
Penbutolol (Levatol) 
Pindolol (generic) 
200 – 800 
10 – 40 
10 – 40 
2 
1 
2 
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1 2 3 4 
Alpha-1 blockers Doxazosin (Cardura) 
Prazosin (Minipress Ɨ)) 
Terazosin (Hetzin) 
1–16 
2–20 
1–20 
1 
2–3 
1–2 
Central alpha-2 
agonists and other 
centrally acting 
drugs 
Clonidine (Catapres Ɨ)) 
Clonidine patch (Catapres – TTS) 
Methyldopa (Aldormet Ɨ)) 
Reserpine (generic) 
Guanfacine (Tenex Ɨ)) 
0.1–0.8 
0.1–0.3 
250–1000 
0.1–0.25 
0.5–2 
2 
1 weekly 
2 
1 
1 
Direct vasodilators Hydralazine (Apresoline Ɨ)) 
Minoxidil (Loniten Ɨ)) 
25–100 
2.5–80 
1 
1–2 
ACEIs Benazepril (LotensinƗ) 
Capropril (CapotenƗ) 
Enalapril (VasotecƗ) 
Fosinopril (Monopril) 
Lisinopril (Prinivil, ZestrilƗ) 
Moexipril (Univasc) 
Peridopril (Aceon) 
Quinapril (Accupril) 
Ramipril (Altace) 
Trandolapril (Mavik) 
10–40 
25–100 
5–40 
10–40 
10–40 
7.5–30 
4–8 
10–80 
2.5–20 
1–4 
1 
2 
1–2 
1 
1 
1 
1 
1 
1 
1 
Angiotensin II 
antagonists 
Candesartan (Atacand) 
Eprosartan (Teveten) 
Irbesartan (Avapro) 
Lorsartan (Cozaar) 
Olmesartan (Benicar) 
Telmisartan (Micardis) 
Valsartan (Diovan) 
8 – 32 
400 – 800 
150 – 300 
25 – 100 
20 – 40 
20 – 80 
80 – 320 
1 
1–2 
1 
1–2 
1 
1 
1–2 
CCBs – non-
dihydropyridines 
Diltiazem extended release (Cardizem CD, 
Dilacor XR, TiazacƗ)) 
Diltiazem extended release (Cardizem LA) 
Verapamil immediate release (Calan, IsoptinƗ) 
Verapamil long acting (Calan SR, Isoptin SRƗ) 
Verapamil – (Coer, Covera HS, Verelan PM) 
180 – 420 
120 – 540 
80 – 320 
120–480 
120–360 
1 
1 
2 
1–2 
1 
CCBs – 
Dihydropyridines 
Amilodipine (Norvasc) 
Felodipine (Plendil) 
Isradipine (Dynacirc CR) 
Nicardipine sustained release (CArdene SR) 
Nifedipine long – acting (Adalat CC, Procardia 
XL) 
Nisoldipine (Sular) 
2.5–10 
2.5–20 
2.5–10 
60–120 
30–60 
10–40 
1 
1 
2 
2 
1 
1 
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1 2 3 4 
Thiazide diuretics Chlorothiazide (Diuril)  
Chlorothialidone (generic) 
Hydrochlorothiazide (Microzide, 
HydroDIURIL) 
Polythiazide (Renese) 
Indapamide (LazolƗ) 
Metolazone (Mylorox) 
Metolazone (Zaroxolyn) 
 
125–500 
12.5–25 
12.5–50 
2–4 
1.25–2.5 
0.5–1.0 
2.5–5 
1–2 
1 
1 
1 
1 
1 
1 
Loop diuretics Bumetanide (BumexƗ) 
Furosemide (LasixƗ) 
Torsemide (DemadexƗ) 
 
0.5–2 
20–80 
2.5–10 
2 
2 
1 
Potassium sparing 
diuretics 
Amiloride (MidamorƗ) 
Triamterene (Dyrenium) 
 
5–10 
50–100 
1–2 
1–2 
Aldosterone 
receptor blockers 
Epelerone (Inspra) 
Spironolactone (AldactoneƗ) 
 
50–100 
25–50 
1 
1 
BBs Atenolol (TenorminƗ) 
Etaxolol (KerloneƗ) 
Bisoprolol (ZebetaƗ) 
Metoprolol (LopressorƗ) 
Metoprolol extended release (Toprol XL) 
Nadolol (CorgardƗ) 
Propanolol (InderalƗ) 
Propanolol long acting (Inderal LAƗ) 
Timolol (BlocardrenƗ) 
 
25–100 
5–20 
2.5–10 
50–100 
50–100 
40–120 
40–160 
60–180 
20–40 
1 
1 
1 
1–2 
1 
1 
2 
1 
2 
BBs with intrinsic 
sympathomimetic 
activity 
Acebutol (SectralƗ) 
Penbutolol (Levatol) 
Pindolol (generic) 
 
200 – 800 
10 – 40 
10 – 40 
2 
1 
2 
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QUESTIONS AND CASES 
 
CASE STUDY 1 
A 48-year-old man with a five-years history of diabetes mellitus comes to the primary care 
clinic for a routine check-up. He has no current complaints. His medications include metformin and 
acetaminophen. He is a teacher, smokes two packs of cigarettes per day, and drinks “occasionally”. 
He eats large amounts of meat daily and consumes excessive "junk food". On physical examination, 
his temperature is 37.1 °C (98.8 °F), pulse 88 bpm, respiratory rate 12 per minute, and blood 
pressure 158/96 mm Hg. His height is 1,7 m, weight is 90 kg. The remainder of his physical 
examination is unremarkable. Laboratory studies reveal HbA1c of 6.5 percent. At his last check-up 
one month ago, his blood pressure was 152/92 mm Hg. 
1. Make the proper diagnosis.  
2. Determine the BMI and the degree of obesity. 
3. Set the grade of arterial hypertension. 
4. Which groups of antihypertensive drugs would be most effective in reducing blood pressure in 
this patient? 
CASE STUDY 2 
A 50-year-old man comes to the office for a review of his laboratory studies. He has a 
history of diabetes mellitus, and his current medications include glipizide and metformin. He says 
that he takes his medications regularly, but his wife is concerned about his diabetes control. His 
health maintenance labs show HbA1c of 9%, increased from 7% at his last visit.  
1. Establish the patient’s clinical diagnosis. 
2. What labs would best indicate a need for insulin to control this patient's blood sugar? 
CASE STUDY 3 
A 34-year-old man comes to the ophthalmology clinic for a routine eye examination. He 
believes his sight is good and has no current concerns. Examination shows bilateral retinal 
microaneurysms and hard exudates. Laboratory studies show HbA1c level of 7.3%.  
1. Make the proper diagnosis. 
2. Prescribe treatment of diabetic retinopathy. 
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CASE STUDY 4 
A 10-year-old girl complaints on increased thirst and urination for 2 months. Her mother 
says that she has also been losing weight over the last month. Personal and family medical histories 
are non-contributory. Examination shows a thin and tired appearing child. She also has dry mucous 
membranes and delayed capillary refill. Laboratory investigations show a blood glucose of 13,4 
mmol/l, an undetectable serum C-peptide and positive anti-islet antibodies. 
1. Make the proper diagnosis. 
2. Prescribe most proper treatment. 
CASE STUDY 5 
A 54-year-old man with type 2 diabetes mellitus of 12 years’ duration with an ulcer over the 
bony prominence on the plantar surface of his rocker bottom deformity which remained unhealed 
for 2 years. He experiences pain after walking over 300 meters. He was referred to the diabetic foot 
clinic and was treated with a total-contact cast and Dermagraft. The foot healed in 7 months and has 
remained healed. X-ray showed multiple feet deformations. Laboratory studies reveal an HbA1c of 
6.7 percent. 
1. Make the proper basic diagnosis.  
 
2. Make the diagnosis of DM chronic complication. 
CASE STUDY 6 
A 53-year-old man comes to the office because of numbness and paraesthesias at the tips of 
his fingers on both hands for 4 months. At night, this sensation sometimes worsens to a burning 
pain. He says he has increased thirst and urination, weight loss, and frustrating impotence during the 
last year. He has decided to leave his career due to these functionally disabling limitations. 
Examination shows decreased sensation of the affected extremities.  
1. What is the basic diagnosis?  
 
2. What is the diagnosis of DM complication? 
CASE STUDY 7 
A 46-year-old woman presents for her yearly physical examination. Her medical history is 
notable only for borderline hypertension and moderate obesity. She has a family history of diabetes 
and hypertension. The patient has not followed the recommended lifestyle changes. Today, her 
blood pressure is 140/90 mmHg, and her BMI is 28 kg/m2. Her examination is notable for 
acanthosis nigricans at the neck. A fasting plasma glucose level is 10 mmol/l. 
1. What is your diagnosis? Explain it. 
2. What is your next step in diagnosis conformation? 
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CASE STUDY 8  
An 18-year-old adolescent female is brought to the emergency room by her mother because 
the daughter seems confused and is behaving strangely. The mother reports the patient has always 
been healthy and has no significant medical history, but she has lost 5 kg recently without trying 
and has been complaining of fatigue for 2 or 3 weeks. The patient has fatigue and sleep disturbance, 
recently she has been getting up several times at night to urinate. This morning, the mother found 
the patient in her room, complaining of abdominal pain, and she had vomited. She appeared 
confused and did not know that today was a school day. On examination, the patient is slender, 
lying on a bad with eyes closed, but she is responsive to questions. She is afebrile, and has a heart 
rate 118 bpm, blood pressure 125/85 mm Hg, with deep and rapid respirations at the rate of 24 
breaths per minute. Upon standing, her heart rate rises to 145 bpm, and her blood pressure falls to 
110/85 mm Hg. Her oral mucosa is dry. Her chest is clear to auscultation, and her heart is 
tachycardic with a regular rhythm and no murmur. Her abdomen is soft with active bowel sounds 
and mild diffuse tenderness, but no guarding or rebound. Her neurologic examination reveals no 
focal deficits.  
Laboratory studies include serum Na 131 mEq/L, K 5.3 mEq/L, Cl 95 mEq/L, CO 
29 mEq/L, blood urea nitrogen (BUN) 35 mg/dL, creatinine 1.3 mg/dL, and glucose 27 mmol/l. 
Arterial blood gas reveals pH 7.12 with PCO2 24 mm Hg and PO2 95 mmHg. Urine drug screen and 
urine pregnancy test are negative, and urinalysis shows no haematuria or pyuria, but 3+ glucose and 
3+ ketones. Chest radiograph is normal. 
1. What is the most likely diagnosis? 
2. What is your next step? 
 
CASE STUDY 9 
A patient comes to the clinic for a fasting plasma glucose test. On two separate occasions, 
the result has been 6.5 mmol/l and 6.7 mmol/l. 
1. What is your diagnosis?  
 
2. What is your management strategy? 
 
CASE STUDY 10 
A 54-year-old male lawyer has uncontrolled diabetes mellitus for over a year. He did not 
take any hypoglycaemic drugs. He has had a previous heart attack and is taking several 
cardiovascular and antihypertensive medications. 
His physical examination today is normal. He admits to feeling a little tired, recently, and 
has been getting up at night to urinate at least two to three times per week.  
Last HbA1C – 9.2 %.  
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Lipid profile: total cholesterol – 4 mmol/l, LDL – 1.8 mmol/l, HDL – 1 mmol/l, 
Triglycerides – 2.5 mmol/l. Creatinine: 0.8 mg/dL.  
Microalbuminuria: negative.  
ALT: normal, AST: normal.  
Postprandial glucose – 13 mmol/l.  
Blood pressure 130/90 mmHg.  
Cardiovascular condition: previous myocardial infarction. Eye examination - normal. Foot 
examination - normal pulses and sensation. His height is 1,67 m, weight is 81 kg. 
1. Establish clinical diagnosis.  
 
2. Determine the BMI and the degree of obesity. 
 
3. Prescribe treatment as well as recommendations. 
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ANSWERS 
 
CASE STUDY 1 
1. Type 2 diabetes mellitus, moderate severity, compensation state. 
2. BMI is 31 kg/m2, obesity I degree. 
3. Grade I of arterial hypertension. 
4. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers. 
 
CASE STUDY 2 
1. Type 2 diabetes mellitus, moderate severity, decompensation state. 
2. The need for insulin to control the blood sugar in this patient is indicated by HbA1c of 9 %. 
 
CASE STUDY 3 
1. Type 2 diabetes mellitus, moderate severity, subcompensation state. Diabetic retinopathy, non-
proliferative stage. 
2. Control of blood sugar level (diet, exercise, medications and/or insulin). 
 
CASE STUDY 4 
1. Type 1 diabetes mellitus, moderate severity, decompensation state. 
2. Basic-bolus intensive insulin therapy with a daily glucose monitoring. 
 
CASE STUDY 5 
1. Type 2 diabetes mellitus, moderate severity, compensation state.  
2. Diabetic foot syndrome grade 2, neuroischaemic form. Diabetic lower extremity angiopathy 
stage 2a. Diabetic bilateral lower extremity sensory neuropathy. 
 
 
CASE STUDY 6 
1. Type 2 diabetes mellitus, moderate severity, decompensation state.  
2. Diabetic neuropathy, sensory form, autonomic form. 
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CASE STUDY 7 
1. Most likely diagnosis: Given her hypertension, obesity, family history, fasting plasma glucose 
level is 10 mmol/l and the finding of acanthosis nigricans, this patient most likely has type 2 
diabetes.  
2. Next step: The fasting/postprandial glucose level should be repeated to confirm the diagnosis. 
If the next result is less than 7 mmol/l, then an oral glucose tolerance test should be performed. 
 
CASE STUDY 8 
1. Most likely diagnosis: diabetic ketoacidosis (DKA). 
2. Next step: rehydration to improve her volume status and insulin therapy to resolve the 
ketoacidosis. See page 83. 
 
CASE STUDY 9 
1. Impaired hyperglycaemia. 
2. Recommend weight loss and lifestyle management. By diagnostic criteria, this patient falls into 
the definition of impaired fasting glucose. Although she does not yet meet the criteria for 
diabetes, she is at greater risk for developing diabetes in the future and for macrovascular 
disease. Interventions such as weight loss will decrease her insulin resistance and following a 
diet lower in simple sugars and fats may place less stress on her pancreas and increase the time 
to development of outright diabetes. 
 
CASE STUDY 10 
1. Type 2 diabetes mellitus, moderate severity, decompensation state. 
2. He has a BMI of 29, overweight. 
3. - Oral hypoglycaemic therapy: metformin 500 mg 3 times daily because patient is overweight, 
and metformin reduces body weight too besides controlling blood sugar level. 
- Anti-lipidemic therapy (statins): atorvastatin 10mg once daily after supper. 
Recommendations: moderate exercise. Diet should contain more fruits and vegetables. Minimize 
the use of fatty foods especially animal fats. 
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APPENDIX G 
INTERACTIVE PRACTICAL EXAM WITH AUGMENTED REALITY ELEMENTS 
 
1. What does this photograph show? 
2. What are the usual sites of these lesions and why do they occur? 
3. What are the possible sequelae? 
 
1. What are the main features of this photograph? 
2. What is the likely underlying cause? 
3. What are the major risk factors? 
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Appendix G continuation 
 
1. What does this photograph show? Where does it usually occur? 
2. What is the natural history of the condition and what are its features? 
3. What are the treatment options? 
 
1. What does this photograph show? 
2. Why is this abnormality in such an unusual site? 
3. What are the possible sequelae? 
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Appendix G continuation 
 
1. What abnormalities are shown in this retinal photograph? 
2. What do these abnormalities signify? 
3. Would you treat this condition, and, if so, what type of treatment would you use? 
 
1. This figure shows a retinal photograph of a 65 year-old, male, type 2 diabetic patient 
complaining of a sudden loss of vision in one eye. What is the diagnosis? 
2. What are the two main causes of visual loss in this condition? 
3. Which factors predispose a patient to this problem and what investigations should be 
performed to confirm the diagnosis?  
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Appendix G continuation  
 
1. What is shown in this photograph? 
2. What may result from this condition? 
3. What is the treatment? 
 
1. This picture is a retinal photograph of a 70 year-old, male patient with type 2 diabetes 
complaining of gradual visual loss. What is the diagnosis? 
2. What are the features, that support the diagnosis? 
3. What urgent investigation should be performed what treatment may be required 
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Appendix G continuation 
 
1. This is a retinal photograph of a 40-year-old female with long-standing type 1 diabetes. What 
abnormalities are shown? 
2. Would the patient be expected to complain of visual problems? 
3. Is treatment required? If so, what? 
 
1. This figure is a retinal photograph of a 50 year-old male with long-standing type 1 diabetes. 
What is the diagnosis? 
2. Explain the findings, that led to the diagnosis? 
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Appendix G continuation 
 
1. This retinal photograph from an asymptomatic 75-year-old female patient shows abnormalities 
detected at her diabetic annual review. Her visual activity was 6/6 bilaterally, but the findings 
prompted a referral to the specialist ophthalmology clinic. What abnormalities are shown and 
what is the diagnosis? 
2. Was the referral appropriate? 
3. What is the treatment? 
 
1. A 60-year-old type 2 diabetic patient of 10 years duration has noted significant deterioration in 
vision on the right (6/60) but maintains a visual activity of 6/6 on the left eye. What two 
different diagnoses are shown? 
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Appendix G continuation  
 
1. This retinal photograph was taken in a 55-year-old female insulin treated diabetic of 20 
years’ disease duration. She was unable to drive at night. What are these appearances and 
suggest a diagnostic label? 
2. This patient is also deaf from the age of 20 years and has two diabetic sons. What, in 
association with the retinal changes, does this suggest? 
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